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ABSTRACT

CHARACTERIZATION OF POTENTIAL ANTI-INFECTIVE AGENTS OF
Burkholderia pseudomallei TARGETING IspF

Joy Michelle Blain, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2016
James R. Horn, Co-Director
Timothy J. Hagen, Co-Director

There is an urgent need for new anti-infective agents. Pathogenic organisms
continue to develop resistance to modern-day antibiotics, while there has been a
significant decline in the development of antibiotics over the last 30 years. One particular
pathway of interest in the development of new antibiotics is the biosynthesis of
isoprenoids. These compounds are essential chemical building blocks in pathogenic
organisms such as Plasmodium falciparum, Mycobacterium tuberculosis, and
Burkholderia pseudomallei. Notably, there are two distinct pathways in the biosynthesis
of isoprenoids called the Mevalonate (MVA) pathway and the 2C-methyl-D-erythritol
phosphate (MEP) pathway. The MEP pathway enzymes are attractive targets in
developing novel anti-infective agents due to the fact that humans only use the MVA
pathway to produce isoprenoids. Burkholderia pseudomallei is a Gram-negative
bacterium found in untreated water and soil in Southeast Asia and northern Australia. The
bacterium has been classified as a category B bioterrorism agent/disease by the category

B bioterrorism agent/disease by the Centers for Disease Control and Prevention.
Antibiotic resistance to traditional anti-microbial agents in such pathogenic organisms
has increased due to the primary mechanisms of resistance, which are enzyme
inactivation, drug efflux from the cell, and target deletion. Consequently, new antiinfective agents targeting B. pseudomallei are of great interest.
The focus of this research project was to examine the inhibition of the fifth
enzyme in the MEP pathway, 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
(IspF) using small molecules that were developed based on fragment hits and structure
activity relationships (SAR). In this study, enzyme engineering was utilized for the
development of a high throughput thermal-shift assay. The assay was used to assess the
relative potency of compounds targeting IspF. The inhibitor binding affinities and
thermodynamics were determined using Surface Plasmon Resonance (SPR) and
Isothermal Titration Calorimetry (ITC). Enzyme inhibition values for the most potent
inhibitors were then evaluated using a High Performance Liquid Chromatography
(HPLC) activity assay. Finally, structural analysis for two compounds in complex with
IspF was completed to assess the mode of binding in the active site, which will aid in
future inhibitor design strategies.
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CHAPTER 1
INTRODUCTION
The use of antibiotics has increased the average human lifespan,1 as well as improved
livestock production,2 due to their ability to minimize the adverse outcomes of bacterial
infections. Despite their importance in human health, the number of FDA approved antibacterial
drugs has significantly decreased since the 1980’s (Figure 1-1).3 Furthermore, since 1985, the
development of antibiotics has declined by greater than 80%, due to the high cost of bringing
these drugs to market. On average, pharmaceutical companies spend $5 billion on research and
development to bring a new drug to market, where approximately 80% of those drugs fail during
testing.4 There were 20 novel classes of antibiotics that were introduced that treat bacterial
infections from 1930 – 1962, but since 1962, there have been only two new classes of antibiotics
that reached the market, with the remainder being structural analogs of the existing 20 classes
(Figure 1-2 and Figure 1-3).5 In the last 5 years, only six antibiotic drugs have been approved by
the FDA.6,7

2

Figure 1-1. FDA approved antibacterial drugs from 1980-2014. Adapted from Ventola3

3

Figure 1-2. Introduction of new classes of antibiotics timeline. Adapted from Walsh.8

4

Figure 1-3. Chemical Structure of antibiotics based on timeline shown in Figure 1-2.

5

Cellular Targets for Antibiotic Development
Antibiotics are generally categorized by their cellular target. Examples of antibiotic
targets/categories include deoxyribonucleic acid (DNA) replication, transcription, protein
biosynthesis, folate biosynthesis, and cell wall biosynthesis (Figure 1-4).7,9,10,11 Inhibiting these
cellular targets would lead to a series of metabolic miscues, such as induction of reactive oxygen
species (ROS), metabolic stress, alteration of cell wall integrity and permeability, mistranslation
of proteins, as well as other effects, all which eventually lead to bacterial cell death.8

6

Figure 1-4. Selected antibiotic targets within the cell. Adapted from Wright.10

7

Inhibition of Cell Wall Biosynthesis- Bacterial cell walls are composed of peptidoglycans,
which are covalently linked peptide-sugar repeats. The peptidoglycans maintain the cell’s shape
and promote survival under harsh environments. The repeating peptide-sugar units are assembled
and maintained by a complex series of enzymatic steps, which include transpeptidases and
transglycosylases.8,9,12 Disruption of the cell wall synthetic machinery compromises the
formation of the cell coat, as well as cell function, often leading to bacterial cell death.
Penicillins and cephalosporins, antibiotics that are classified as -lactams, are able to covalently
modify and inhibit transpeptidases that cross-link the peptidoglycan units (Figure 1-5).
Analogously, vancomycin binds to D-alanyl-D-alanine dipeptide of NAM/NAG-peptides, Nacetylglucosamine and N-acetylmuramic acid. This action blocks transglycosylase and
transpeptidase activity thereby inhibiting peptidoglycan biosynthesis.9

8

Figure 1-5. Drug-target interaction of -lactams inhibition of cell wall biosynthesis. Adapted
from Kohanski8 (yellow circle: autolysin, green circle: penicillin-binding protein, pink triangle:
-lactam)

9

Inhibition of DNA/RNA Synthesis- Levofloxacin and Ciprofloxacin are examples of
antibiotics that inhibit DNA replication by targeting topoisomerase II and IV, enzymes that are
involved in the breaking and rejoining of DNA, to increase or reduce DNA supercoiling, as it
proceeds through replication. Topoisomerases from eukaryotes and bacteria are structurally and
functionally distinct, which allows selective targeting of pathogenic topoisomerases. The
aminocoumarins and quinolone class of antibiotics target DNA gyrase, a bacterial
topoisomerase. These antibiotics stall DNA replication by trapping the topoisomerase as it
breaks and re-ligates the DNA strand (Figure 1-6). The antibiotic subclass of rifamycin, from the
family of ansamycine, targets the synthesis of ribonucleic acid (RNA) from DNA. Rifamycin is a
natural product that acts allosterically, blocking nascent RNA transcript initialization, as it binds
the exit site of a previously initiated transcription reaction in RNA polymerase.7,8 Disruption of
these replication/transcription steps would ultimately initiate a DNA stress response mechanism
that leads to bacterial cell death.8

10

Figure 1-6. Drug-target interaction of topoisomerase inhibition by quinolones. Adapted from
Kohanski8 (pink circle: topoisomerase and purple triangle: quinolone)

11

Inhibition of Protein Biosynthesis-The translation of RNA to protein involves three steps,
which are initiation, elongation, and termination. The translation machinery are anchored on the
ribosome as it progresses along the RNA, resulting in the final peptide product. After
biosynthesis the peptide can undergo processes such as post-translation modification and protein
folding. The bacterial ribosome is made up of two subunits 50S and 30S. The larger of the two
subunits, 50S, is targeted by the lincosamide, clindamycin, amphenicols, oxazolidinones, and the
macrolide erythromycin. The smaller subunit, 30S, is targeted by tetracyclines and
aminocyclitols. The mechanism by which these inhibitors work is by blocking initiation or
translation of peptides. Changing the peptide synthesis fragments by alteration of factors
associated with initiation and elongation or through obstruction of access to the amino acid
building blocks can result in blocking peptide initiation and translation that results in cell death
(Figure 1-7).7,8
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Figure 1-7. Drug-target interaction of aminoglycoside inhibition of protein biosynthesis. Adapted
from Kohanski.8 (beige triangle: aminoglycoside, blue rectangle: membrane protein)
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Mechanisms of Antibiotic Resistance
The use of antibiotics has resulted in a dramatic increase in human life expectancy, as
otherwise deadly bacterial infections can typically be treated.13 Despite the important role
antibiotics have played in improving human health, their overuse, as well as misuse, has led to
increased bacterial resistance. Bacteria, through often sophisticated mechanisms, develop
methods to evade the antibiotic’s mechanism of action. In a review by Soares, et al., the
mechanisms of bacterial resistance against antibiotics were described as falling into three
categories: efflux of the antibiotic from the cell, modification of the antibiotic target, and
inactivation of the antibiotic (Figure 1-8).10,14

14

Figure 1-8. Mechanisms of antibiotic resistance by cellular targets. Adapted from Wright.10
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Two examples of antibiotic resistance are observed with quinolone-based antibiotics.
These include alteration of the target and over expression of efflux pump systems and/or
impermeability of the membrane. On the other hand, antibiotic resistance of -lactam antibiotics
is due to deactivation by -lactamase enzymes, which hydrolyze the -lactam core.
Alternatively, resistance to vancomycin is caused by bacteria utilizing a low-affinity precursor,
D-alanine-D-lactate or D-alanine-D-serine, which replaces the high-affinity precursor D-alanineD-alanine. In turn this causes modification of the vancomycin-target binding. Finally, in the vast
majority of observed antibiotic resistance cases, there is a decrease in membrane
permeability.9,11,12,,15
Investigation of Novel Classes of Antibiotics and Novel Targets
The problem with antibiotic resistance is magnified due to the lack of new antibiotics,
with only two new classes introduced since 1962. The majority of anti-bacterials that have been
developed are derived from known scaffolds. To effectively combat antibiotic resistance requires
the identification of novel classes of antibiotics with distinguishing scaffolds. In addition,
antibiotic disruption of pathways not been previously targeted will help delay the emergence of
antibiotic resistance.
Known targets of antibiotics- One strategy of developing novel classes of antibiotics is
exploitation of known targets, such as protein biosynthesis and cell wall biosynthetic pathways.
Antibiotic classes such as macrolides and � –lactams, including erythromycin and penicillin,
target these two essential bacterial cellular processes and are highly effective. Targeting these
two pathways is a particularly interesting approach due to the many components involved in
these processes. Many of these components are still being activity studied. While transpeptidases
are well studied and amply targeted by numerous �-lactam antibiotics, the transglycosylases and
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the machinery involved in the assembly of the target polysaccharide portion of the cell wall still
remain a viable target for exploration in developing new classes of antibiotics. Furthermore, the
size and diverse components of the translation machinery leave potential for development of
novel classes of antibiotics that target the ribosome and ribosomal subunits.5
Targeting Bacterial Genes that are Essential- An alternative method of introducing new
classes of antibiotics entails delving into the genomes of known pathogens to identify conserved
and essential pathways or genes. Antibiotics that target proteins that are not present in mammals
are often ideal, as they possess reduced potential for cross-reactivity. There were >350 genes
identified by Payne et. al that participate in bacterial pathways. The identified genes encoded
proteins participating in cell division, lipid metabolism, nucleotide and amino acid metabolism,
partitioning of chromosomes, protein secretion, and signal transduction, as well as other bacterial
pathways.16 Especially attractive examples identified by the study are the genes involved in
bacterial communication and bacterial infectivity, which were found to be essential and
constitutively expressed. Virulence factors, which are molecules responsible for the
pathogenicity of bacteria,17 along with the proteins involved in biofilm formation have recently
been investigated as potential anti-infective targets. The ability to inhibit bacterial infectivity to
the host (virulence) as well as disrupt communication through biofilms would improve clearance
of the weakened pathogen from the host.18,19 Researchers have also explored bacteriolytically
therapeutics, such as bacteriophage-derived lysins, which can damage cell wall peptidoglycans
selectively without disturbing normal microbiota. For example, in extracellular infections, lysins
that are able to influence the pathogen within the host could eradicate the infection prior to
inactivation of the lysin by the host immune response.,19,20
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Biosynthesis of Isoprenoids as a Potential Anti-Infective Target- The biosynthesis of
isoprenoids is a vital process in all-living organisms, including pathogenic organisms.
Isoprenoids are a large class of natural products and metabolites in nature, also known as
terpenoids, with over 40,000 compounds characterized which include drugs, lipids, and
hormones.21,22 The structural diversity of isoprenoids is immense and includes carotenoids,
dolichols, quinones, steroids, and sesquiterpenes (Figure 1-9). Isoprenoids are taxonomically
widespread and involved in multiple biological functions such as hormone signaling, electron
transport, post-translational regulation of lipid biosynthesis, protein cleavage and degradation,
membrane structure, and transcription regulation. The structural diversity of this large class of
natural products are wholely derived from differences in only two, five-carbon subunits,
dimethylallyl pyrophosphate (DMAPP) and isopentyl pyrophosphate (IPP). These two subunits,
DMAPP and IPP, are products of two independent pathways in nature called the mevalonate
(MVA) pathway in eukaryotes and the 2C-methyl-D-erythritol 4-phosphate pathway (MEP) in
higher order eukaryotes and many bacteria.23,24,25,26
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Figure 1-9. Representation of the biosynthesis of isoprenoid from the isoprene building blocks
dimethylallyl pyrophosphate (DMAPP) and isopentyl pyrophosphate (IPP). Adapted from
Tachibana.27
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Two Distinct Isoprenoid Biosynthetic Pathways for Mammalians and non-Mammalians
Mammalian Isoprenoid Biosynthetic Pathway The mevalonate pathway (MVA) was first
recognized in the late 1950s.28 Consisting of six enzymatic steps,29 the MVA pathway converts
two acetyl Coenzyme A (Ac-CoA or acetyl-CoA) molecules to DMAPP and IPP (Figure 1-10).
In the first reaction, two molecules of acetyl-CoA are condensed by the enzyme acetoacetyl-CoA
thiolase to give acetoacetyl-CoA. The product is then converted by HMG-CoA synthase to 3hydroxy-3-methylglutaryl-CoA (HMG-CoA) by addition of another acetyl-CoA molecule.
Reduction of HMG-CoA is facilitated by HMG-CoA reductase (HMGR) to mevalonate, which
then undergoes two phosphorylation steps by mevalonate kinase and phosphomevalonate kinase
to produce mevalonate-5-diphopshate. In the final step, the intermediate mevalonate-5diphosphate is decarboxylated to IPP, which can be converted to DMAPP by IPP isomerase. 30
Besides mammals, the mevalonate pathway has also been identified in archaea, some eubacteria,
fungi, and higher order plants.26
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Figure 1-10. Biosynthesis of DMAPP and IPP in the mevalonate (MVA) pathway.
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Discovery of the Non-mammalian Isoprenoid Biosynthetic Pathway -Until the early
1990’s, the MVA pathway was thought to be the single source of DMAPP and IPP biosynthesis
until the discovery of the methylerythritol phosphate (MEP) pathway. 21,31,32 When studying
triterpenoid biosynthesis in Rhodopseudomonas palustris bacteria, Rohmer, et al. found that the
carbon isotope labeling distribution was not consistent with the expected labeling pattern for the
MVA pathway (Figure 1-11b), suggesting the existence of an alternate non-MVA isoprenoid
pathway. 28,33,34 Similarly, Brechbuhler-Bader, et al., observed inconsistencies with 13C labeling
patterns in plants.35 In 1991, Zhou and White found that supplementing bacterial cells with [13C]glucose, which is metabolized by the glycolytic pathway (Figure 1-11a), incorporated the label
into the isoprene chain of ubiquinone, a quinone-based analog (Figure 1-9). On the other hand,
when bacteria were supplemented with unlabeled glucose and [13C]-acetate there was no labeling
of the ubiquinone chain. When bacteria were supplemented with doubly labeled [4,5-13C]glucose, conclusive evidence was found that isoprenoids in bacteria resulted in the condensation
of C2 from pyruvate and C3 from G3P units, thereby explaining the observed labeling pattern
(Figure 1-11C).28,31,36Arioni, et al., found that plants also utilize the MEP pathway due to
incorporation of [13C]-labeling in DMAPP and IPP using [13C]-deoxyxylulose.37
Over time, algae, bacteria, plants, and many other pathogenic organisms were found to
exploit the MEP pathway. Two important examples are the highly infectious agents
Mycobacterium tuberculosis and Plasmodium falciparum, among other Apicomplexan parasites.
Due to mammalians exclusive use of the MVA pathway as a source of isoprenoid biosynthesis,
the MEP pathway enzymes have been identified as promising targets in the development of
novel anti-infective agents as well as herbicides.21,38,39
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a) Glycolysis

b) MVA Pathway

c) MEP Pathway

Figure 1-11. The elucidation of the MEP pathway by feeding [13C]-labeled carbon sources to
bacterial. a) [13C]-labeled glucose metabolism by glycolysis. b) Predicted integration of the
[13C]-label by the MVA pathway. c) Observed integration of the [13C]-label by the MEP
pathway.
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Methylerythritol Phosphate (MEP) Pathway an Attractive Target for Developing Novel
Antibiotics

The enzymes of the methylerythritol phosphate (MEP) pathway (also referred to as the
non-mammalian isoprenoid biosynthetic pathway) (Figure 1-12), became the target of novel antiinfective agents in the early 1990’s.7 The MEP pathway presents a new class of targets as well as
the potential for developing a new class of antibiotics. The MEP pathway utilizes seven enzymes
in the biosynthesis of DMAPP and IPP that starts with pyruvate and D-glyceraldehyde 3phosphate (D-G3P) to form DXP, which is catalyzed by 1-deoxy-D-xylulose 5-phosphate (DXP)
synthase (Figure 1-12). DXP is then converted to 2C-methyl-D-erythritol 4-phosphate (MEP) by
reductoisomerase IspC, which is the first committed step of the MEP pathway. MEP undergoes
cytidylation by IspD with a cofactor of cytidine triphosphate (CTP) followed by phosphorylation
by IspE with adenosine triphosphate to form 4-diphosphocytidyl-2C-methyl-D-erythritol 2phosphate (CDP-ME2P). The fifth enzymatic step, which is the focus of this dissertation,
catalyzes the cyclization of CDP-ME2P to 2C-methyl-D-erythritol 2,4-cyclodiphosphate
(MEcDP) with the release of a cytidine monophosphate (CMP). The enzyme IspG then performs
a reductive ring opening of MEcDP to form (E)-4-hydroxy-3-methylbut-2-enyl diphosphate
(HMBDP) and the final enzymatic step is performed by a reductase, IspH, to generate the
isoprene building blocks DMAPP and IPP.
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Figure 1-12. The biosynthesis of DMAPP and IPP by the methylerythritol phosphate (MEP)
pathway.
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MEP pathway Regulation- The regulation of the MEP pathway in pathogens is not well
known.22,40 Brown, et al., determined that overexpression of the gene dxs, which encodes DXP
synthase, in Mycobacterium tuberculosis leads to accumulation of the downstream product
HMBDP of the MEP pathway via IspC (Dxr) and IspG (GcpE) upregulation. These results
suggested DXP synthase is involved in transcriptional control, consequently it would control flux
at the beginning of the pathway. Furthermore, the authors proposed IspG (GcpE) was the ratelimiting step of the pathway.37 IspD and IspF are expressed as a bifunctional IspDF enzyme in
certain organisms such as Campylobactor jejuni, Mesorhizobium loti, and Agrobacterium
tumefaciens.22,41,42,43 Multiple studies have focused on the bifunctional IspDF enzyme as a
prospective regulatory mechanism in the biosynthesis of isoprenoids. It is known to catalyze the
conversion of MEP to MEcDP in a number of bacterial species. In early reports, RodriguezConcepcion proposed the IspDF organization of enzymes within the pathway could increase flux
by substrate channeling through a complex of IspDF/IspE.39 Research by Lherbbert, et al., did
not observe an increased metabolic flux through the IspDF complex, which suggests that the
bifunctional enzyme serves in some other regulatory role.44
Known MEP Pathway Inhibitors- The MEP pathway has been validated as a target for the
development of inhibitors as potential antibiotics. The first inhibitor discovered targeting DXP
synthase was Fluoropyruvate (Figure 1-13, 1), a pyruvate mimetic, that after elimination of the
fluoride ion during decarboxylation will generate a deactivated acetylated cofactor.45 The
utilization of library screens identified arylpyrimidinone (2) as a DXP synthase inhibitor with an
IC50 value in the low micromolar range.46 The molecule ketoclomazone (3), which is a known
herbicide, was also found to target DXP synthase.47 In 2012, Smith, et al., showed
acylphosphonates could selectively inhibit Escherichia coli DXP synthase when they contain a
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methyl-, ethyl-, or butyl- group at the phosphorus center with a inhibition constant, Ki, in the low
micromolar range.48
The most potent inhibitor of the MEP pathway, fosmidomycin (Figure 1-10, compound
4), targets the second enzyme, IspC. Fosmidomycin and analog FR-900098 (compound 6), both
phosphonate-containing compounds, are substrate mimetics that inhibited two malarial parasites,
Plasmodium falciparum and Plasmodium vinckei.49,50 In combination with clindamycin, a protein
biosynthesis inhibitor, fosmidomycin was evaluated in Phase III clinical trials for treating
malaria. The results from the clinical trial showed that the dual-compound treatment, while
showing efficacy, was not a cure for malaria in all patients.51 Currently, Phase II clinical trials
are being performed using fosmidomycin in combination with piperaquine as a non-artemisininbased therapy for acute noncomplicated Plasmodium falciparum.52 Subsequent experiments have
found that the phosphonate, hydroxamate, and the propyl linker were important for
fosmidomycin activity.53 Therefore, this reduced potential active derivatives to compounds such
as compound 5.42 Results for compounds containing an aryl ring at the -position, compound 8,
had varied results due to the size.54
Developing inhibitors against the remainder of the enzymes within the MEP pathway has
been difficult due to the relatively polar nature of their active sites, which possess pockets that
electrostatically complement the substrate’s diphosphate groups. There have been two reported
inhibitors of IspD with one being a substrate mimetic, desmethylerythritol (compound 8) that
binds at the active site55 and another that was found to bind to an allosteric site of the enzyme
(compound 9), which is the most potent IspD inhibitor to date.56 IspE was also found to be
sensitive to substrate analogs that contain a cytidine (compound 10).57 The most potent inhibitor
of IspE, which is a kinase, was an alkyne-sulfonamide (compound 11) that contains a
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tetrahydrothiophene substituent as a mimetic of the cytidyl ribose ring. Initial IspF inhibitors
mimicked the CDP-ME2P substrate preserving the cytidyl moiety and replacing the
methylerythritol portion with a fluorescent group (compound 12).58 Baumgartner, et al., found
that modifying these inhibitors increased the IC50 into the upper micromolar range (compound
13).59 In 2010, the most potent IspF inhibitor was reported with an IC50 value in the low
micromolar range (compound 14), which contained a thiazolopyrimidine core.60 Inhibitors of
IspG and IspH have also included the diphosphate functional group (compounds 15 & 16) as
well as the bisphosphonate group (compound 17). The propylargyl diphosphate (compounds 15
& 16) actually showed activity against both IspG and IspH while the pyridyl analog (compound
17) was only active against IspH.45
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Figure 1-13. Substrates of MEP pathway enzymes and their known inhibitors (Adapted from
Hale (et al.).45
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Targeting Cyclodiphosphate Synthase (IspF)
IspF is of great interest as a target to disrupt the biosynthesis of isoprenoids since it has
been shown to be essential in multiple pathogenic organisms such as Mycobacterium
tuberculosis,61 Escherichia coli, Bacillus subtilis.62 Beutow, et. al,61 attempted an IspF knockout
mutant in M. tuberculosis but was only successful in isolating the mutant when a functional copy
of the gene was co-introduced. In another study, ispF and yacN (IspF homolog) genes were
deleted in E. coli and B. subtilis, which resulted in altered growth rates and morphology.62 The
results of these studies determined that the ispF gene is essential in M. tuberculosis, E. coli, and
B. subtilis.
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Figure 1-14. Proposed IspF mechanism displaying the substrate position and charge stabilization
by Mg2+ and Zn2+.65
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Figure 1-15. Ribbon representation of Escherichia coli IspF crystal structure. Highlighted is one
of the three active sites located at the monomer-monomer interface. IspF co-crystallized with the
products MEcDP, CMP, and the metal co-factors (PDB: 1H48 and 1U3L).63,64 IspF has also been
shown to bind downstream isoprenoid intermediates in the hydrophobic cavity such as geranyl
pyrophosphate (GPP). 63
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Active Site of Cyclodiphosphate synthase (IspF)- IspF has been proposed to be
physiologically active as a trimer with three active sites located between the three symmetrical
monomer-monomer interfaces (Figure 1-15).65 It also requires two metal co-factors, Zn2+ and
Mg2+, which stabilize the charge of its pentavalent transition state (Figure 1-14).26,64,66,67,68,69
The crystal structure of E. coli IspF reveals three active site sub-binding pockets, named Pocket I,
II, and III, which bind the ribosyl group, methylerythritol group, and the cytidyl nucleotide base,
respectively (Figure 1-16).58,64 Pocket I encloses the riboxyl-5’-diphosphate moiety and has a
conserved Asp46 at the bottom of the active site, it also has no direct interaction with the
substrate. Pocket II was shown to contain a flexible loop (residues Pro62 to Ala71) that
becomes well-ordered upon binding the substrate MEcDP. Furthermore, the pocket contains
hydrophobic residues Ile57 and Leu76, as well as hydrophilic residues Ser35, Ser73, and Asp63
that orients the C-methyl-D-erythritol phosphate moiety for attack by the -phosphoryl group.
Pocket III was observed to bind the cytidine group. The pocket is formed by Ala131, Thr133,
Lys104, and Leu106. Additionally, Pocket III binds the nucleobase with four hydrogen bonds
provided by residues Ala100 to Leu106 (Figure 1-17).64 As shown previously, the Mg2+ and Zn2+
ions are important for catalyzing the IspF reaction. In particular, the Zn2+ ion coordinates to
Asp8, His10, and His42 and attacks the -phosphoryl group, which coordinates the ion
tetrahedrally. The Mg2+ ion holds the - and -phosphates of CDP-ME2P to prepare for the 2phosphoryl attack on the -phosphoryl center, which thereby stabilizes the negative charge
that develops on the CMP.64
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Figure 1-16. Sub-binding pockets within the active site of Escherichia coli IspF (PDB: 1H48)63
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Figure 1-17. Active site diagram of Escherichia coli IspF highlighting cytosine-enzyme
interactions. Cytosine ring has four hydrogen bonds with the backbone of Ala102 to Leu106,
Pocket III. (PDB: 1H48)63
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Cyclodiphosphate synthase (IspF) Hydrophobic Cavity-Structural studies have shown he
presence of a hydrophobic cavity in the channel of the IspF homotrimer (Figure 1-14),63,65,66,67
which has been observed to accommodate downstream isoprenoids. Richard, et al. found that the
polar diphosphate of geranyl diphosphate (GDP) interacts with an arginine “cap” within the
hydrophobic cavity that was first reported in 2004.63,65 The arginine “cap”, which consists of
three arginines, was shown to coordinate to a sulfate ion when downstream isoprenoids were not
present.65 Further structural studies by Kemp, et al.67 and Ni, et al66 showed that farnesyl
diphosphate (FDP) could also be trapped in the hydrophobic cavity. 31P NMR and mass
spectrometry studies showed that GDP predominately binds in the cavity.67 Kemp, et al. also
found that the downstream isoprenoids IDP, GDP, and FDP bound to EcIspF with a ratio of
1:4:2,but this finding was not confirmed with structural studies.67 Additionally, crystallographic
studies on a double mutant of the enzyme, R142M and E144L, disrupted six hydrogen bonds to
the diphosphate moiety but maintained binding of the isoprenoid diphosphate group. This
indicates that the hydrophobic interactions with the ligand dominate binding of the downstream
isoprenoids.61 Overall, this suggests the potential for feedback regulation of the MEP pathway by
inhibiting IspF with downstream isoprenoids.70
Targeting Burkholderia pseudomallei IspF- In 2004, Eberl, et al. used a TBLASTN
search of E. coli homologues which identified that Burkholderia pseudomallei utilizes the MEP
pathway.71 Studies have shown that the IspF product, 2C-methyl-D-erythritol 2,4cyclodiphosphate (MEcDP), accumulates to high levels in a variety of organisms as a response to
oxidative stress.72,73,74,75,76,77,78 This implicates MEcDP could act as an anti-stressor through
metal-dependent enzyme regulation by chelation of cations or antioxidant regulation.
Goncharenko, et al. found that adding MEcDP to a “nonculturable” form of Mycobacterium
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smegmatis would reactivate growth in vitro, which suggests it may play a role in the transition to
and from latency79 involving chromatin condensation-decondensation regulation. This result
coupled with the fact that IspF binds downstream isoprenoids suggest cyclodiphosphate synthase
IspF could regulate the MEP pathway.
The goal of this research project was to develop and implement assays to study small
molecule inhibitors on the fifth enzyme in the MEP pathway, IspF, from Burkholderia
pseudomallei in an effort to identify lead molecules as potential anti-infective agents. This
dissertation will describe the development of a high-throughput thermal shift assay to assess
relative binding potencies of potential IspF inhibitors (Chapter 2). The most potent compounds
were analyzed using Surface Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC),
and Fluorescence Polarization (FP) to determine dissociation constants and the binding
energetics (Chapter 3). The most promising compounds were tested for their ability to inhibit
Burkholderia pseudomallei IspF using a HPLC-based enzymatic assay (Chapter 4). Finally, Xray crystallography was used to study the mode of inhibitor binding and future inhibitor design
(Chapter 5).

CHAPTER 2
DEVELOPMENT OF A HIGH-THROUGHPUT THERMAL SHIFT ASSAY TO ASSESS
THE RELATIVE AFFINITY OF BURKHOLDERIA PSEUDOMALLEI ISPF
INHIBITORS

In drug discovery, it is imperative to have a method to assess the ability of compounds to
bind or inhibit the target. This step is crucial to help guide the next step in molecular design for
increased affinity, selectivity, and specificity. A high-throughput assay is preferred when
screening a large library of compounds to rapidly identify compounds that are the most potent.
Chemical libraries typically consist of thousands to hundreds of thousands of compounds with
diverse chemical structures that can easily be modified for synthesis of analogs.
The current methods reported in the literature to assess IspF activity do not have a direct
readout of the enzymatic product due to the absence of a chromophore in 2-C-methyl-Derythritol 2,4-cyclodiphosphate. Consequently, established IspF enzyme inhibition assays are
either highly complex and/or labor-intensive. In 2006, Rohdich reported the first IspF assay
which consisted of a plate-based assay using three additional enzymes that allows monitoring the
consumption of nicotinamide adenine dinucleotide (NADH) (Figure 2-1).80 An alternative IspF
assay was reported by Freel-Meyers in 2012, which utilizes an HPLC method to monitors the
formation of the by-product, cytidine monophosphate (Figure 2-2).81 The HPLC method is a
time-intensive
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assay that requires 36 hours to acquire an 8-point dose-response curve. In a third approach,
reported in 2011, the product CMP is used to generate ADP in the presence of ATP and
nucleotide monophosphate kinase. Through the use of three enzymes, ADP can then be
converted to resorufin, which fluoresces at 590 nm (Figure 2-3).82 Consequently, the
development of a simple and rapid method to directly assess the relative affinity of compounds
in a high throughput manner would be advantageous in screening potential IspF inhibitors.

Figure 2-1. Plate-based IspF assay by coupling cytidine monophosphate to monitor NADH
consumption.81

CDP-ME2P

MEcPP

CMP

Figure 2-2. HPLC method to monitor IspF activity using the cytidine chromophore of the
substrate and cytidine monophosphate that is released.82
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Figure 2-3. Plate-based assay converting CMP to ADP, which is then converted to resorufin for
detection.83

Thermal-shift assays have been used successfully in drug discovery efforts.83,84,85,86 These
assays monitor the unfolding of the target enzyme in the absence and presence of inhibitors to
identify compounds that result in a significant shift in the enzyme’s melting temperature (e.g., ≥4
º C), which indicates the compounds are stabilizing the native state of the enzyme. Analyzing all
compounds at the same concentration can provide a rank order of potency, as the degree of shift
is proportional to the affinities of the compounds for the enzyme. As B. pseudomallei IspF was
found to be extremely thermostable, with a melting temperature >100°C at physiological pH, a
thermal shift analysis was not possible. In this study, enzyme engineering was utilized to develop
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a high-throughput IspF thermal shift assay by destabilizing the enzyme to lower the temperature
at which it unfolds. Furthermore, similar to naturally observed destabilized enzymes, 87,88 the
identified IspF variant Q151E possessed decreased stability without loss of enzyme activity.

Methods

Expression and Purification of Burkholderia pseudomallei IspF

An IspF expression vector, IspF-pET14b (Novagen), which possesses an N-terminal
hexa-His tag before the IspF gene, was obtained from the SSGCID. Starting from a single
colony, a 5-mL (LB- 100 µg/mL ampicillin) culture of E. coli BL21(DE3) containing the
pET14b-His-3C-IspF89 was grown overnight at 37°C. The overnight culture, 500 µL, was used to
start a 50mL subculture that was used to inoculate a 1 L (LB-100 µg/mL ampicillin) culture once
mid-log phase was reached. Cells were grown at 37°C until the OD600 reached 0.5-0.8. The
culture was induced with isopropyl �--D-thiogalactoside (IPTG, 1 mM) and allowed to shake
overnight (20 C, 235 rpm). The cells were harvested by centrifugation (8000 rpm, 20 min) and
stored at -20C.
The frozen pellet was resuspended in 10 mM TRIS pH 8.0 and sonicated for six cycles of
20 sec on/20 sec off with a Branson 450 digital sonicator followed by centrifugation at 4°C (20
min, 15,000 rpm) to pellet insoluble protein and cell debris. The soluble fraction was loaded onto
an immobilized Ni2+ affinity column (Histrap HP, GE Healthcare). The His-tagged IspF was
eluted using a 70-mL linear gradient from 20 mM to 500 mM imidazole (in 50 mM sodium
phosphate, 500 mM NaCl, and 1 mM DTT). The single peak corresponding to IspF was further
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purified on a HiLoad 26/60 Superdex 75 prep grade FPLC size exclusion column (20 mM TRIS
and 150 mM NaCl).90

Table 2-1 DNA and Protein Sequence of Burkholderia pseudomallei IspF
DNA Sequence ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGTTCGATGGATT
TCAGAATCGGACAAGGCTACGACGTGCACCAGCTCGTTCCCGGACGCCCGCTCATCATCGGCGGCGTGA
CGATCCCTTACGAGCGGGGGCTGCTCGGCCACTCGGACGCCGACGTGCTGCTGCACGCGATCACCGAC
GCGCTCTTCGGCGCGGCGGCGCTCGGCGACATCGGCCGCCACTTCTCCGACACCGATCCGCGCTTCAAG
GGCGCCGACAGCCGCGCGCTGTTGCGCGAATGCGCATCGCGCGTCGCGCAGGCGGGTTTTGCGATCCG
CAACGTCGACAGCACGATCATCGCGCAGGCGCCGAAGCTCGCGCCGCATATCGACGCGATGCGCGCGA
ACATCGCGGCCGATCTCGACTTGCCGCTCGATCGCGTGAACGTGAAGGCGAAGACGAACGAGAAGCTC
GGCTATCTCGGGCGCGGTGAGGGGATCGAGGCGCAGGCGGCCGCGCTCGTCGTGCGCGAAGCGGCCG
CGTGAAAACAGCACGAACAAGTTCTGCA
Protein Sequence MAHHHHHHMGTLEAQTQGPGSMDFRIGQGYDVHQLVPGRPLIIGGVTIPYERGLLGHSDADVLLHAITDA
LFGAAALGDIGRHFSDTDPRFKGADSRALLRECASRVAQAGFAIRNVDSTIIAQAPKLAPHIDAMRANIAADL
DLPLDRVNVKAKTNEKLGYLGRGEGIEAQAAALVVREAAA

Circular Dichroism

All experiments were performed on an Aviv Instruments circular dichroism spectrometer
model 215. Wavelength scans were carried out at 25oC from 250 to 200 nm in phosphatebuffered saline (PBS) (10 mM sodium phosphate, 150 mM sodium chloride, pH 7.4) or a
chemical denaturant phosphate buffer (10 mM sodium phosphate, 150 mM sodium chloride, 4M
guanidine hydrochloride). A quartz cuvette was used with a 1-mm path length. IspF temperature
denaturation experiments were monitored at 222 nm over a temperature range of 25 to 100°C at
1oC/min, 2 nm bandwidth, and 2 second averaging time. The melting temperatures, Tm values,
were determined using a Boltzmann fit with Origin Labs.
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Solvent Accessible Surface Area

The high resolution crystal structure of Burkholderia pseudomallei IspF (PDB: 3QHD)90
was used to calculate solvent accessible surface areas with the NACCESS program91 using a
water sphere with a 1.4

radius and a slice width of 0.25 . An in-house Fortran program92 was

used to determine the change in solvent accessible surface upon folding (ASA). The ASA
value was partitioned into the change in polar (ΔASApol) and apolar (ΔASAap) surface area upon
folding.

Computational Stability Measurements

The program FoldX allows the assessment of the effect single and multiple mutations
may have on protein stability, folding, and dynamics.93 Here, stability calculations, performed
using FoldX, were used to identify residue substitutions that may destabilize IspF. Specifically,
two approaches were used: (1) isosteric introduction of charged residue (either Asp or Glu) at the
interface of two monomers and (2) substitution of bulky hydrophobic residues with alanine. Both
strategies are aimed at destabilizing the favorable packing interactions that lead to IspF’s high
thermal stability. Twelve single point mutations were identified based on the two criteria: I5A,
Q7E, Q13E, Q88E, N95D, N117D, N130D, N136D, L139A, R144A, Q151E, and L155A.
Before analysis using FoldX in Yasara, RepairPDB was run on a representative crystal structure
of IspF (PDB: 3MBM)90 to optimize residues that have high energy torsion angles or clashes.
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FoldX was used to calculate the predicted change in stability (ΔΔG°) for the twelve mutants
based on the following equation:
;

Eq. 2-1

where ΔΔG° values less than zero are predicted to be stabilizing mutants and those values greater
than zero are predicted to be destabilizing mutants.93

Site-Directed Mutagenesis of Burkholderia pseudomallei IspF

Starting with a modified pET14b vector containing Burkholderia pseudomallei IspF, sitedirected mutagenesis was carried out to create single point mutations. A total of 50 ng of
template dsDNA was mixed with 10X reaction buffer, forward oligonucleotide (125 ng/µL),
reverse oligonucleotide (125 ng/µL), 10 mM dNTP, 2% v/v DMSO, and PfuTurbo DNA
polymerase (2.5 U/µL). Site-directed mutagenesis was performed using a Bio-rad iQ5 Real-Time
PCR with one cycle at 95oC for 30 seconds, which was followed by a second cycle at 95oC for
30 seconds, 55 oC for 60 sec, and 68 oC for 6 minutes, repeated sixteen times. DPN-1 (20 U/µL),
1 µL, was added to the reaction tube and incubated at 37oC for 1 hour. The DPN-1 digested PCR
product was then transformed into XL-1 Blue competent cells using standard methods. Single
colonies were picked and grown overnight in 5 mL LB/Amp at 37 oC in a tabletop incubator
shaker. DNA was isolated using the Promega Wizard Plus SV Miniprep DNA Purification
System and sent for sequence verification at the University of Chicago Comprehensive Cancer
Center DNA Sequencing and Genotyping Facility.
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Table 2-2. Primers used for site-directed mutagenesis of Burkholderia pseudomallei IspF
Primer

Sequence (5’→3’)

I5A Forward

GGATTTCAGAGCGGGACAAGGCTACGACGTGCACCAGCTCGTTCC

I5A Reverse

GGAACGAGCTGGTGCACGTCGTAGCCTTGTCCCGCTCTGAAATCC

Q7E Forward

GATTTCAGAATCGGAGAAGGCTACGACGTGC

Q7E Reverse

GCACGTCGTAGCCTTCTCCGATTCTGAAATC

Q13E Forward

GCTACGACGTGCACGAACTCGTTCCCGGACG

Q13E Reverse

CGTCCGGGAACGAGTTCGTGCACGTCGTAGC

Q88E Forward

ATCGCGCGTCGCGGAAGCGGGTTTTGCGA

Q88E Reverse

TCGCAAAACCCGCTTCCGCGACGCGCGAT

N95D Forward

GTTTTGCGATCCGCGACGTCGACAGCACG

N95D Reverse

CGTGCTGTCGACGTCGCGGATCGCAAAAC

N117D Forward

CGATGCGCGCGGACATCGCGGCC

N117D Reverse

GGCCGCGATGTCCGCGCGCATCG

N130D Forward

CGCTCGATCGCGTGGACGTGAAGGCGAAG

N130D Reverse

CTTCGCCTTCACGTCCACGCGATCGAGCG

N136D Forward

AAGGCGAAGACGGACGAGAAGCTCGGCTAT

N136D Reverse

ATAGCCGAGCTTCTCGTCCGTCTTCGCCTT

L139A Forward

CGAACGAGAAGGCGGGCTATCTCGGGCGCGG

L139A Reverse

CCGCGCCCGAGATAGCCCGCCTTCTCGTTCG

R144A Forward

GCTCGGCTATCTCGGGGCAGGTGAGGGGATCG

R144A Reverse

CGATCCCCTCACCTGCCCCGAGATAGCCGAGC

Q151E Forward

GGGATCGAGGCGGAAGCGGCCGCGC

Q151E Reverse

GCGCGGCCGCTTCCGCCTCGATCCC

L155A Forward

GGCGGCCGCGGCGGTCGTGCGCGAAGC

L155A Reverse

GCTTCGCGCACGACCGCCGCGGCCGCC
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Thermal Shift Assay

Small molecule screening by fluorescence based thermal unfolding was performed using
a Bio-Rad iQ5 Real-Time PCR equipped with a 96-well PCR plate. Purified Burkholderia
pseudomallei IspF mutants were diluted to the appropriate concentration with a buffer consisting
of 100 mM Glycine-NaOH, pH 9.0, 100 mM NaCl, and 100 mM NaI. All assay experiments
contained 5 µg enzyme per well and 4X SYPRO orange dye with a final volume of 25 µL,
resulting in an enzyme concentration of 4 µM. Compounds were dissolved at 10 mM in DMSO
and serial diluted into the assay buffer to a final concentration of 500 µM with 25% DMSO, with
a resultant final concentration of 100 µM per well. The PCR plates were sealed with optical seal,
shaken, and centrifuged after enzyme and compound were added. Thermal scanning (25-95oC at
1.0oC/min) was performed and fluorescence intensity (ex. 530 nm em. 570 nm) measured every
10 seconds in 0.5oC increments. The melting temperature was determined using the first
derivative of the raw fluorescence intensity to identify the peak minimum.

Preparation of 4-diphosphocytidyL-2C-methyl-D-erythritol 2-phosphate (CDP-ME2P)

CDP-ME2P was prepared following a modified procedure of Bitok et al.81 A mixture of
MEP (5 mM), CTP (5 mM), E. coli IspD (2 µM), inorganic pyrophosphates (7 units), BSA (1
mg/mL) in 50 mM HEPES (pH 7.4) was incubated at room temperature for 128 minutes to
facilitate the conversion of CTP (2.38 min) to CDP-ME (1.56 min). The reaction was monitored
at 272 nm using a Varian Prostar reverse phase HPLC with ion-pairing reagent tetrabutyl
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ammonium. The column, Altima C18 3 µ, 53 mm x 7 mm Rocket column, was run using a
gradient of 0-33.5% Buffer B at a flow rate of 1.5 mL/min to elute the analytes of interest
(Buffer A = 100 mM phosphate buffer, 5 mM tetrabutyl ammonium bisulfate, pH 6.0 and Buffer
B = 100 mM phosphate buffer, 5 mM tetrabutyl ammonium bisulfate in 30% acetonitrile). Once
the IspD reaction was complete, phosphonenol pyruvate (7 mM), pyruvate kinase (3.5 units), and
LeIspE (2 µM) was added to the reaction mixture with continued monitoring by HPLC for CDPME2P formation (CDP-ME2P = 2.47 min) after 182 minutes.81

HPLC-based IspF Activity

IspF reaction mixtures contained 50 mM phosphate buffer, pH 7.4, 5 mM MgCl2, 100
µM CDP-ME2P, 2 nM BpIspF and 50 µg/mL BSA in a total volume of 250 µL. All reactions
were performed at 25 oC. The reaction, initiated by the addition of IspF, was terminated at 2, 4, 6,
and 10 min by addition of 40 µL of reaction mixture to 80 µL of cold 0.1% SDS. The quenched
reaction mixture was vortexed for 5 seconds. Before HPLC analysis proteins were removed
using a 3 kDa MWCO VWR Polyethersulfone Membrane centrifugal filter. Using a Varian
Prostar HPLC with PEEK tubing, samples (100 µL) were injected into a reversed-phase ion-pair
HPLC with an Altima C18 3 µ, 53 mm x 7 mm Rocket column. The column used a gradient of
0-33.5% Buffer B at a flow rate of 1.5 mL/min to elute the analytes of interest (Buffer A = 100
mM phosphate buffer, 5 mM tetrabutyl ammonium bisulfate, pH 6.0 and Buffer B = 100 mM
phosphate buffer, 5 mM tetrabutyl ammonium bisulfate in 30% acetonitrile). The peak areas of
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CMP (1.24 min) and CDP-ME2P (2.47 min) were determined and the concentration of CMP was
calculated as a fraction of the total peak area.81

Crystallization of Burkholderia pseudomallei IspF Q151E

Purified BpIspF (13 mg/mL) was run on a Superdex 75 10/30GL size exclusion column
(GE Healthcare) using a 20 mM HEPES pH 7.0, 150 mM NaCl, 2 mM DTT running buffer.
Fractions corresponding to a single peak representing trimeric IspF were pooled and
concentrated to 32 mg/mL using an Amicon ultrafiltration device with a 3 kDa cut-off
membrane. Protein crystals were grown using the hanging drop vapor diffusion method. The
trays were incubated at 19oC and BpIspF crystals were observed in three days. Initial
crystallization drops were composed of 1.0 µL protein solution (32 mg/mL of BpIspF in SE
buffer) and 1.0 µL crystallization buffer (100 mM Tris, pH 7.2, 200 mM NaCl, 20% PEG 4000,
5 µM ZnCl2 or 200 mM C2H2MgO4∙2H2O, pH 5.9, 20% PEG 3350). The crystallization tray
wells contained 1000 µL of crystallization buffer.90

X-Ray Diffraction

Crystals were loop mounted and flash frozen in a glycerol containing cryoprotectant
solution and loop mounted using standard methods.94 Briefly, for each crystal growth condition,
2X-concentrated cryoprotectant stocks were prepared by mixing 100% glycerol with crystal tray
well solution to a final glycerol concentration of 40% (v/v). Prior to crystal mounting, 0.5 µL of
the 2X-concentrated cryoprotectant stock was diluted two-fold by adding an equal volume of
crystal growth drop solution. Crystals were then immediately transferred from the growth drop
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using an appropriately sized LithoLoop mount (Molecular Dimensions) and briefly washed in the
cryoprotectant solution. Crystals were then re-looped, flash frozen by immersion in a liquid
nitrogen bath, and seated in the appropriate wells of a Unipucks (MiTeGen), which had been
chilled in a liquid nitrogen bath. Pucks containing the samples were transferred to the beamline
and samples were mounted for data collection using the robotic automounter provided at the
beamline.

Data were collected at Southeast Regional Collaborative Access Team (SER-CAT) 22BM beamline95 at the Advanced Photon Source, Argonne National Laboratory.96 The beamline
energy was tuned to 12.398eV (1.000Å). A total of 180-degrees of data were collected from each
sample, using a 1-second per 1-degree oscillation range. Data were collected at a distance of 140
mm on a MAR 225 CCD detector (Rayonix LLC, Evanston IL, USA). Data were processed
using HKL2000.97

X-Ray Structure Solution

All IspF structures in this study were determined using molecular replacement. Molecular
replacement was performed using Phaser98 with Burkholderia pseudomallei IspF (PDB ID:
3QHD)90 as the input model. One or two IspF molecules were observed in the asymmetric unit,
dependent upon the crystal form (form 1 or 2: C2 with a = 157.7 or 116.9, b = 69.4 or 68.1, c =
116.4 or 60.4). The Phenix program suite was used for all refinements.99 The ligand, along with
residues that were not modeled in the input structure, were built into observed electron density
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using iterative rounds of refinement and manual model building with Phenix, Refmac, and
Coot.18,100,101

Results and Discussion

Purification of Burkholderia pseudomallei IspF

The wild-type and mutant IspF enzymes were purified using a Ni2+ affinity column with a
gradient elution from 50 mM to 250 mM imidazole (Figure 2-4). Fractions containing protein
were collected, from 25-35 minutes, and concentrated to a volume of ten milliliters using a 3000
MWCO spin concentrator. Further purification was performed using a Sephadex-75 prep grade
size exclusion chromatography (SEC) column. Fractions containing protein were collected from
90-100 minutes (Figure 2-5). The purified protein was stored at -80°C and aliquots removed as
needed for circular dichroism analysis, the thermal-shift assay, and the HPLC activity assay.
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Figure 2-4. Chromatogram of Ni2+ affinity purification of Burkholderia pseudomallei IspF.
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Figure 2-5. Size exclusion chromatogram of Burkholderia pseudomallei IspF purification.
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Determination of Burkholderia pseudomallei IspF Melting Temperature

The thermal stability of the enzyme was evaluated using circular dichroism at an IspF
concentration of 10 µM in an effort to develop a thermal-shift assay to assess the relative
affinities of inhibitors. Initially, a far-UV scan was performed from 250-200 nm. The analysis
confirmed the expected alpha helical and beta sheet secondary structure of the enzyme (Figure 26).102 Surprisingly, a thermal melt did not show any loss of secondary structure up to 100°C
(Figure 2-7). Subsequently, to promote unfolding, the enzyme was incubated with a chemical
denaturant, guanidine hydrochloride. In the presence of 4 M guanidine hydrochloride the melting
temperature was determined to be approximately 92°C (Figure 2-7). The exact melting
temperature could not be determined due to an incomplete unfolding transition. Despite the
addition of a high concentration of chemical denaturant, the enzyme maintained a high thermal
stability. This result indicated that such an approach would not be viable for a useful thermalshift assay to assess IspF inhibitors. For this technique to work, at least two conditions must be
met. First, the range of temperature over which thermal denaturation is observed must be
sufficiently broad to allow clear identification of the temperature of the unfolding event. Second,
the melting temperature cannot be too close to the maximum temperature for the technique
(100°C). The native IspF, even in the presence of the chemical denaturant guanidine
hydrochloride, violates both requirements.
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Figure 2-6. Wavelength scan of trimeric Burkholderia pseudomallei IspF displaying alpha helical
and beta sheet characteristics.
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Figure 2-7 Thermal unfolding of wild-type enzyme in the presence (open squares) and absence
(filled triangles) of 4 M guanidine HCl.
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Identification of Burkholderia pseudomallei IspF Destabilizing Mutants

Due to the extreme thermostability of BpIspF, an alternative approach was devised to
develop a high throughput assay for screening inhibitors. Identification of amino acid residues
that could be mutated to affect thermal stability of the enzyme was analyzed. In order to generate
useful thermal destabilizing mutants of the enzyme, amino acid residues that do not affect
enzyme activity had to be identified, which likely involved residues distant from the active site.
Two approaches were used to engineer a destabilized IspF with the disruption of monomermonomer packing interactions and the introduction of charged residues. The first approach
analyzed each IspF residue for both apolar and polar surface burial (Table 2-3). Mutagenesis of a
residue that is found to have a large apolar surface area to a much smaller amino acid, such as
alanine, reduces the hydrophobic interactions that drive packing efficiency and will likely
destabilize the native state of the enzyme. Using this protocol, three hydrophobic residues within
the subunit interfaces were calculated to have a significant loss in apolar surface area that upon
mutation to alanine that could lead to destabilization: I5A, L139A, and L155A (Figure 2-8).
Additionally, the arginine “cap” is in close proximity to a sulfate ion located within the channel
of the homotrimer (Figure 5-2). Due to its close proximity to the sulfate ion, it was hypothesized
that mutating R144 would eliminate binding and destabilize the enzyme. The second approach
involves introducing buried charged residues to create an energetic penalty. Aspartate and
glutamate mutations were substituted for isosteric asparagine and glutamine residues,
respectively. The specific mutations made were at positions: Q7E, Q13E, Q88E, N95D, N117D,
N130D, and Q151E. Based on the crystal structure of IspF (PDB: 3QHD)90 the positions for
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mutagenesis were found to be 12-25 Å from the active site (Figure 2-8). Next, FoldX was used
to calculate ΔΔG values for destabilization (Figure 2-9). It is important to note, these values
represent one-third of the predicted stabilization or destabilization effect due to the trimeric
nature of the IspF structure. A total of eleven residues were predicted to have a destabilizing
effect (ΔΔGfold>0) based upon their mutation to alanine (approach 1) or to an isosteric, charged
residue (approach 2). Mutagenesis of Arg144 to an alanine was the only change predicted to
have an overall stabilizing effect (Figure 2-9).
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Table 2-3. Analysis of surface burial of individual residues of the Burkholderia pseudomallei
IspF enzyme. (PDB: 3QHD)90
res#
1
2
3
4
5
6
7
8
9
10
11
12
13
34
35
44
48
52
53
54
55
57
58
59
61
94
95
96
97
98

res
MET
ASP
PHE
ARG
ILE
GLY
GLN
GLY
TYR
ASP
VAL
HIS
GLN
LEU
GLY
HIS
ASP
GLY
ALA
ALA
ALA
GLY
ASP
ILE
ARG
ARG
ASN
VAL
ASP
SER

ap tot
4.23
12.96
66.32
36.16
110.87
8.61
44.25
0.75
81.61
5.64
41.75
20.2
28.52
5.62
4.98
0.08
10.37
18.26
0.62
0
52.94
20.99
20.43
7.74
0
1.6
16.44
0
17.12
3.52

pol tot
55.09
12.41
20.11
44.91
12.87
2.51
67.74
1.41
17.02
15.19
12.84
7.36
32.91
4.86
0
0
29.19
15.73
3.95
0.95
7.14
10.94
33.35
0
9.63
25.91
39.52
0.18
28
0

res#
99
101
108
111
112
115
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
144
146
151
152
153
154
155
158
-

res
THR
ILE
ALA
ILE
ASP
ARG
ASP
ARG
VAL
ASN
VAL
LYS
ALA
LYS
THR
ASN
GLU
LYS
LEU
GLY
TYR
ARG
GLU
GLN
ALA
ALA
ALA
LEU
ARG
-

ap tot
3.51
16.09
8.1
22.8
4.41
0
1.69
15.16
0.88
17.64
0
83.5
1.82
57.7
0
4.67
47.87
12.63
108.25
16.89
62.44
0
4.61
7.13
3.35
42.84
1.99
46.4
0
-

pol tot
13.27
0
7.41
0
19.65
18.69
39.12
40.69
0.69
36.87
12.46
1.78
17.3
38.37
4.05
37.3
24.48
0
0
3.06
4.15
2.11
7.29
41.91
0.96
0.69
1.83
0
13.74
-
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Figure 2-8. Ribbon representation of Burkholderia pseudomallei IspF homotrimer highlights
interdomain mutation designed to decrease protein stability (magenta). The homotrimer contains
three subunits that are designated by the following color scheme A (cyan), subunit B (pale cyan),
and subunit C (green cyan). All three monomers contain a single zinc ion (blue spheres). The B
subunit zinc ion is not visible in the picture rotation.
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Figure 2-9. FoldX stability predictions for single point mutations.
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Melting Temperature Determination of Burkholderia pseudomallei IspF Mutants

The twelve single point IspF mutants were generated by site-directed mutagenesis and
then expressed and purified according to the same procedure that was used for the wild-type
IspF. The mutants were then analyzed to determine the melting temperature under three separate
conditions (Figure 2-10). The first condition studied was physiological pH (7.4) where a total of
three mutants were found to have a destabilizing effects. All three destabilization mutants
involved the incorporation of a charged residue that decreased the melting temperature by 1331°C: N95D, N130D, and Q151E. The next condition examined was pH 9.0, which was
predicted to introduce additional folding penalties for the acid residue substitution by favoring
generation of a formal charge on the mutant residues: Q7E, Q13E, Q88E, N95D, N117D,
N130D, N136D, and Q151E. The three mutants that were destabilized at physiological pH were
destabilized even further (by 6-22°C). One additional mutant, Q7E, was also destabilized at this
pH (by 20°C). In an attempt to lower the melting temperature further, several alternative
chemical denaturants and salts to guanidine hydrochloride were analyzed in the presence of all
BpIspF single point mutations. Of note, sodium iodide displayed a destabilization effect on all
variants and wild-type enzyme. The iodine molecule is larger than a chlorine and therefore can
disrupt interactions between hydrophobic residues.103 The disruption of those interactions can
further destabilize the enzyme to a temperature that can aid in the rank ordering of inhibitor
binding using this type of assay.5 Overall, the addition of the chemical denaturant NaI showed a
significant destabilization effect on all single point mutants, by 12-34°C. In addition, NaI acted
as a better chemical denaturant on the wild-type enzyme in comparison to guanidine
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hydrochloride. The N130D and Q151E showed the most significant destabilization of the
enzyme at >53°C and >36°C, respectively. To ensure the mutants were binding an inhibitor
similarly to the wild-type IspF, the two mutants were initially screened with a control inhibitor,
L-tryptophan hydroxamate. The N130D mutant was determined not to bind the compound and
was therefore not used in the thermal-shift assay. The Q151E mutant, however, displayed the
same binding affinity for the compound as the wild-type IspF and could therefore be used in the
thermal-shift assay to analyze potential IspF inhibitors.
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Figure 2-10. Melting temperatures analysis of Burkholderia pseudomallei IspF mutants under
various conditions. (* indicates the melting temperature could not be detected and is >100°C)
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Enzymatic Activity of Burkholderia pseudomallei IspF

For this study, enzyme activity was a mandatory criterion in identifying usable
destabilizing mutations. Although the twelve identified mutations involved changes that were
distant from the active site, this did not guarantee that the mutants would maintain native IspF
activity, so this had to be tested. Consequently, the Q151E variant, which was destabilized by
>36°C and bound the control compound with similar affinity as wild-type enzyme, was
examined for activity using the HPLC assay. Enzymatic activity was analyzed to determine the
rates of both the wild-type and Q151E variant. The rate of the wild-type was measured as 4.3 ±
0.3 µmol/min and the mutant was measured to be 6.0 ± 1.0 µmol/min (Figure 2-11). Overall, the
rates of both the wild-type and mutant enzyme were found to be similar indicating that the active
site of the enzyme was not affected by mutating glutamine to glutamate at position 151.
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Figure 2-11. Enzymatic reaction rate of Burkholderia pseudomallei IspF Q151E mutant. The
Q151E mutant was determined to have a rate of 6.0 ± 1.0 µmol/min (blue squares) in comparison
to native IspF (green squares).
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Structure of Burkholderia pseudomallei IspF Mutant Q151E

Structural analysis using X-ray crystallography confirmed the Q151E variant did not
significantly affect the structure of the IspF enzyme. An overlay of the structures for the wildtype and Q151E mutant of IspF showed that the quaternary structure of the enzyme was not
affected by incorporation of a charged residue within each monomer-monomer interface (Figure
2-12). In addition, Q151E displayed only minimal differences in side chain conformation relative
to the wild-type (Figure 2-13). Finally, examination of the wild-type versus mutant active sites
verifies that the close proximity of the charged residue to the active site did not modify the
binding pocket (Figure 2-14).
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Figure 2-12. Overlay of Burkholderia pseudomallei IspF wild-type and Q151E mutant. The wildtype structure (PDB: 3F0D)90 is shown in cyan and the crystal structure determined for the
Q151E mutant in this study is displayed in magenta. (RMSD: 0.152 Å)
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Figure 2-13. Side chain comparison of the Q151E mutant (magenta) shows small differences
structurally due to incorporating a charged residue. (RMSD: 0.3 Å)
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Figure 2-14. Active site overlay of Burkholderia pseudomallei IspF wild-type and Q151E mutant
confirms active site was unaffected by mutagenesis. The IspF structure (PDB: 3F0D)90 is shown
in cyan and the crystal structure solved for the Q151E mutant is displayed in magenta. (RMSD:
0.152 Å)
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Analysis of BpIspF Q151E Melting Thermal-shifts in Presence of Inhibitors

The mutant enzyme Q151E was successfully destabilized, resulting in a Tm of 64°C. This
represents at least a 36°C decrease in Tm relative to wild-type IspF. Because this variant also
maintained a wild-type level of activity, its use was justified to examine inhibitor binding using
the thermal-shift assay. This high-throughput assay can be used to efficiently screen compounds
for their apparent affinity. Since the magnitude of the thermal-shift is dependent upon both the
concentration and binding affinity of the inhibitor, a relative ranking of inhibitor binding
affinities can be determined by keeping the concentration of inhibitor constant. The compounds
that display the highest apparent affinity, defined as those displaying a shift in melting
temperature of ≥4°C, were then tested in an alternative assay to determine dissociation constants.
A total of four chemical series were studied using the temperature assay to determine a rank
order of compound affinities.
Previous research on IspF inhibitors found coordination to the active site zinc was
important for binding. This mechanism of action has been observed for other classes of enzymes.
For example, matrix metalloprotease (MMP) inhibitors are known to bind to the active site zinc
via coordination by three histidine residues, similar to IspF. Furthermore, it has been shown that
these inhibitors typically contain a peptidomimetic backbone that chelates with the zinc (Figure
2-15)104,105 In collaboration with Dr. Michael Clare at Emerald Biostructures, a similar strategy
was used to design a new chemical series that mimics MMP inhibitors, which contained 5 or 6member ring systems (Figure 2-16). The first chemical series (synthesized by Zheng Zhang)
consisted of thirty-one compounds based around a common pyrimidine core (Table 2-4). The
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thermal-shift assay indicated that the pyrimidine substituents which contain hydrogen bond
donor/acceptor groups have an overall higher apparent affinity (Figure 2-18). These compounds
employ a similar mechanism of binding to that of the IspF substrate, CDP-ME2P, which also
contains hydrogen bond donor/acceptor groups in the cytosine ring that hydrogen bonds to the
enzyme (Figure 2-17). Therefore, these analogs could be utilizing the same interactions as the
cytosine ring and increasing the affinity of the ligand for IspF. In addition, the compounds that
were converted to disodium salts were in general more active than their ethyl ester counterparts
likely due to increased solubility. The pyrimidine core is expected to coordinate to the active site
zinc and the substituents are proposed to bind in the cytidine pocket, where the hydrogen bond
donor/acceptor can interact with the backbone of the enzyme.

Figure 2-15 Observed binding model of various MMP inhibitors that mimic peptidomimetic
backbone inhbitors.104,105
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Figure 2-16 The 6 and 5-member zinc binding molecules designed to mimic MMP inhibitors.
Where X = Y = O or N.

Figure 2-17 Active site of E. coli IspF displaying hydrogen bonding of cytosine ring to
backbone. (PDB: 1H48)63
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Figure 2-18 Example of normalized thermal-shift assay in the absence and presence of
compound. The black squares represent the unfolding of BpIspF in the presence of 5% DMSO as
a control. The open triangles display the shift in melting temperature in the presence of 100 M
of compound 2 containing 5% DMSO.

Table 2-4 continued
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Table 2-4. Table of potential pyrimidine IspF inhibitors synthesized for this study. The Tm
determined in the thermal-shift assay assesses the relative ranking of pyrimidines binding to
IspF.
ΔTm @ 100
Compound
Structure
µM

1

6.0

2

5.5

3

5.5

4

5.0

5

4.7

6

4.5

Continued on following page
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7

4.0

8

3.2

9

3.2

10

3.0

11

3.0

12

2.8

13

2.8

Continued on following page
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14

2.7

15

2.7

16

2.5

17

2.5

18

2.5

19

2.5
Continued on following page
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20

2.5

21

2.3

22

2.2

23

2.2

24

2.0

25

1.5

26

1.5
Continued on following page
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27

1.0

28

0.8

29

0.7

30

0.3

31

0.2

Continued on following page
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Surface plasmon resonance has also been used to study binding of potential Escherichia
coli IspF inhibitors.106 The study showed that L-tryptophan hydroxamate bound to E. coli IspF
with a Kd,app of 2 µM. Four tryptophan analogs, the two enantiomers of the amino acid as well as
their hydroxamate derivatives, synthesized by Gashaw Goshu, were evaluated using the thermalshift assay for their ability to bind Burkholderia pseudomallei IspF (Table 2-5), which possesses
30% sequence identity to E. coli IspF. The results demonstrated that the hydroxamate derivatives
possessed a higher relative affinity compared to their respective amino acids (Table 2-5). The
hydroxamate functional group in MMP inhibitors is known to coordinate to the active site zinc
through a tetrahedral or trigonal bipyramidal geometry (Figure 2-15).107 Overall these
interactions are predicted to increase the apparent affinity of the ligand by providing more
interactions to the enzyme. In addition, L-tryptophan hydroxamate exhibited a slightly larger
shift in melting temperature than D-tryptophan hydroxamate and is expected to bind with higher
affinity to the IspF. This result is probably not surprising since most enzyme active sites are
stereospecific and designed to operate only on the L-enantiomorphs of chiral compounds, since
that form is more prevalent in nature.
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Table 2-5. Tryptophan analogs synthesized to study IspF binding.

Compound

Structure

ΔTm @ 500 µM

1

5.5

2

5.2

3

3.3

4

3.3
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The last two chemical series studied in the thermal-shift assay are structurally similar,
both containing an imidazole ring. The first is an imidazothiazole series (synthesized by Gashaw
Goshu). The series includes two thiazolopyrimidine compounds, which are structurally similar to
the imidazothiazole core, which can be considered as controls based on literature reports
demonstrating they are inhibitors of IspF from plant, parasitic, and bacterial organisms with IC50
values between 10 µM and 200 µM108 (Table 2-6). The two control compounds 1 and 2
generated thermal shift values >17°C against Burkholderia pseudomallei IspF. The
imidazothiazole analogs have three positions available for substitution, two located on the
imidazole ring (R1 and R2) and one on the thiazole ring (R0) (Figure 2-19). A general trend
observed in the imidazothiazole series was substitution at R1 and R2, increased the apparent
affinity (Figure 2-20). Substitutions at these positions are predicted to primarily extend into the
cytidine pocket for potential for interactions. These ligands can potentially hydrogen bond with
the backbone of the enzyme resulting in the increased apparent affinity (Figure 2-17).
Substituents at R0, which points towards the lipophilic pocket, were found to bind with a lower
apparent affinity when the substituent was bulky. It is hypothesized that the lipophilic pocket
cannot accommodate the bulky substituents, with the notable exceptions of 3 and 5.

Figure 2-19. Imidazothiazole compounds contained substituents at C2 (R0), C5 (R1), and C6
(R2).
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Figure 2-20 Crystal structure of BpIspF in complex with FOL717 displaying interactions of
imidazole ring substituents with the cytidine pocket. BpIspF is shown in cyan with the ligand
FOL717 (magenta) N4 binding to zinc (1.9Å) and the hydroxyl group hydrogen bonding to K134
(2.9Å). (PDB: 3MBM) 90
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Table 2-6. Imidazothiazole series thermal-shift analysis for apparent binding affinity.
Compound Structure

ΔTm @ 500 µM

1

18.8

2

17.1

3

8.3

4

5.8

Continued on following page
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5

5.8

6

4.3

7

4.3

8

4.3

Continued on following page
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9

3.6

10

3.5

11

2.7

12

2.5

13

1.0

14

0.8

Continued on following page
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15

0.7

16

0.7

17

0.6

18

0.6

19

0.5

20

0.5

21

0.5

Continued on following page
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22

0.5

23

0.5

24

0.5

25

0.3

26

0.3

27

0.3

Continued on following page

Table 2-6 continued

86

28

0.3

29

0.2

30

0.2

31

0.2

32

0.2

33

0.2

Continued on following page
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34

0.0

35

0.0

36

0.0

37

0.0

38

0.0

39

0.0

Continued on following page
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40

0.0

41

-0.2

42

-0.2

43

-2.2

Continued on following page
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The final series examined in the thermal-shift assay were the imidazole compounds
synthesized by Zheng Zhang and Gashaw Goshu (Table 2-7). In general, the apparent affinities
of the imidazole compounds were shown to be weaker than the imidazothiazole series (lower
ΔTm values). The phenyl substituents that are di-substituted (3, 4, 6, and 7) with an electronwithdrawing group were more potent than those that are mono-substituted (5, and 10-17). There
was one compound observed to have a significant destabilization effect in the imidazole series,
compound 30, which was quite interesting, suggesting it may favor binding to the unfolded state
relative to the native state. Alternatively, it may bind strongly to zinc ions such that it chelates
metal ions, thus decreasing IspF stability. Although the inhibitor destabilized the enzyme it could
still be a good inhibitor potentially due its strong binding affinity for zinc if it bound IspF in a
sequence/structure-dependent manner. Therefore, compounds that are found to have a significant
negative thermal shift should not be eliminated from screening in the determination of
dissociation constants.

Table 2-7 continued
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Table 2-7. Imidazole series thermal-shift analysis for apparent binding affinity.
Compound
Structure
ΔTm @ 500 µM

1

4.5

2

3.7

3

3.7

4

3.5

5

3.5

Continued on following page
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6

3.5

7

3.3

8

3.3

9

3.2

10

3.2

Continued on following page
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11

3.2

12

3.0

13

2.8

14

2.7

15

2.5

Continued on following page
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16

2.5

17

2.5

18

2.3

19

1.8

20

1.8

Continued on following page
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21

1.8

22

1.7

23

1.3

24

1.0

25

1.0

Continued on following page
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26

0.8

27

0.5

28

0.3

29

-7.2

Continued on following page
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Conclusions
Due to BpIspF’s high thermostability, a protein engineering approach was used to
destabilize the enzyme allowing the development of a thermal-shift assay to evaluate potential
small molecule inhibitors. Analysis of twelve single point mutants using the program FoldX
yielded estimates of destabilization ΔΔG° values for each variant of the enzyme. Eleven variant
forms of the enzyme were predicted to destabilize BpIspF. These mutants were produced and
analyzed, with three variants displaying destabilization at physiological pH. As a result of these
mutants, the thermostable enzyme Burkholderia pseudomallei IspF was destabilized sufficiently
to produce a Tm value at which small molecule inhibitors could be reliably analyzed for apparent
binding affinity by monitoring unfolding temperatures. Additionally, of these three mutants, the
Q151E variant was found to not affect enzyme activity and was therefore used as the basis for a
thermal-shift assay. The use of a high-throughput thermal-shift assay provided a rank order of
apparent affinities within four chemical series. This allowed the library of compounds to be
narrowed down to a reasonable number of compounds for subsequent experimental analysis to
determine dissociation constants. These methods for incorporating isosteric charged residues into
any target protein of interest could be further refined and optimized as a broadly applicable
approach to developing high throughput thermal-shift assays for enzymes that possess extreme
thermostability.
Thermal-shift assays have been used across a wide variety of applications, such as the
identification of Bacillus anthracis PurE inhibitors85 Toxoplasma gondii Enoyl-Acyl Carrier
Protein Reductase inhibitors,109 the recognition of caffeine and analogs of caffeine by an anticaffeine camelid antibody,110 as well as the stabilization of CC-chemokine receptor 5 by small
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molecules.

Here, the engineering BpIspF variant opens new opportunities for the thermal-shift

assay to be used to evaluate compounds that bind the target, BpIspF.

CHAPTER 3
CHARACTERIZATION OF BINDING AFFINITY OF BURKHOLDERIA
PSEUDOMALLEI ISPF INHIBITORS

The determination of a ligand’s affinity for an enzyme can be measured by a variety of methods
such as mass spectrometry (MS),112,113,114,115 fluorescence polarization (FP),116,117,118 isothermal
titration calorimetry (ITC),119,120,121 nuclear magnetic resonance (NMR),122,123,124 and surface
plasmon resonance (SPR).125,126,127 Each technique has its own advantages and disadvantages in
the determination of the ligand’s affinity for the enzyme. For example, NMR and MS are wellsuited for efficiently screening large compound libraries to quickly identify a subset of molecules
that bind to the active site of an enzyme target. Such reduced compound subsets can then be
evaluated using titration experiments to determine binding affinities.114,123,115 FP, first reported
in 1920,128 was used for high throughput screening in the 1990s, often in competitive binding
assays.116 However, there are inherent limitations with FP assays, such as inconsistent probe
fluorescence at high concentrations (>100 µM), non-specific interactions, and compound
aggregates, which can make determining ligand affinity difficult.5 SPR has been used since the
1990s to analyze protein binding thermodynamics and kinetics.129,130 Similarly in the 1990s, ITC
became widely employed in drug discovery to examine the thermodynamic profile of ligandenzyme interactions.131 ITC has the advantage of being able to study enzyme-ligand interactions
at lower concentrations due its ability to detect small differences in heats of reaction.
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One of the major limitations for any of these techniques in obtaining weak affinity dissociation
constants for small organic ligands that bind their protein targets weakly (Kd values mM to μM)
is solubility. This chapter will discuss the analysis of BpIspF inhibitor dissociation constants
determined using ITC, SPR, and FP.

Methods
Surface Plasmon Resonance (SPR)
SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF
was coupled to the sensor slide using amine coupling chemistry132 (Figure 3-1). Initially, the
surface was activated by injecting a mixture of 80 mg/ml EDC (N-Ethyl-N′-(3dimethylaminopropyl)carbodiimide hydrochloride) and 20 mg/ml NHS (N-hydroxysuccinimide)
for 7 min using a 50 μl/min flow rate. IspF, diluted to a final concentration of 120 μg/ml in 10
mM 4.5 pH sodium acetate buffer, was injected over the surface for 7 min at 30 μl/min. Excess
succinamide ester groups were quenched with an injection of 1M ethanolamine for 3 min with a
50 μl/min flow rate. A total of 4000-8000 μRIU (Refractive index units) of IspF was coated on
the slide. Binding experiments were conducted at 25°C in running buffer (50 mM sodium
phosphate pH 7.4/150 mM NaCl/4.76% DMSO) at 50 μl/ min. Compounds were dissolved in
DMSO to initial concentrations between 4-20 mM, dependent upon solubility. These were
further diluted (20-fold) into running buffer to produce a final concentration of 200-1000 μM
compound with 4.76% DMSO, thereby minimizing buffer mismatch. Compounds were serially
diluted two-fold using running buffer and injected over the IspF surface. Blank (running buffer
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only) injections were included between each compound injection, allowing for double
subtraction (reference cell and buffer) during data processing. Data processing and analysis were
performed using Scrubber (BioLogic Software).

Figure 3-1. Overview of BpIspF coupling chemistry. A 500,000 Da carboxymethyl dextran
SR7000 gold sensor slide (sphere) was used to coat BpIspF on the surface via EDC/NHS
coupling chemistry. The surface was first activated with EDC to form an o-Acylisourea leaving
group. N-hydroxysuccinimide was then used to convert the activated carboxylate to an NHS
ester intermediate, which is a good leaving group. The amine groups in the enzyme can then
form amide bonds with the activated surface.
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Isothermal Titration Calorimetry
ITC experiments were performed using a Microcal VP-ITC titration calorimeter
(Microcal, LLC, Northampton, MA). Buffers were matched for all ITC experiments by dialyzing
the protein overnight against 4L of dialysis buffer (20 mM sodium phosphate monobasic, pH 7.4,
150 mM NaCl). The ligand was dissolved in the dialysis buffer and centrifuged for 5 min at
14,000 rpm. The extinction coefficient of BpIspF (11,560 M-1 cm-1 at 280 nm) was determined
with 6M guanidine hydrochloride based using the Edelhoch method.133 Protein and ligand
concentrations were measured in triplicate and the average value was used to calculate the final
IspF concentration. The concentrations of the tryptophan analogs were calculated by measuring
absorbance at 280 nm using the published extinction coefficient of tryptophan (5540 M-1 cm1 134

).

The concentrations of fusion compounds were based on dry weight. The ITC experiments

were performed with BpIspF (cell) and ligand (syringe) diluted to appropriate concentrations in
dialysis buffer. All experiments included a total of 28 injections with each injection being
separated by 240 seconds at 25°C with a stirring speed of 307 rpm. The initial injection was 2
μL, which was omitted in data processing, to account for dilution across the syringe. The

remaining injections were 10 μL. Dilution heats of the ligand were measured in a separate
experiment by injecting the ligand (syringe) into dialysis buffer (cell). Data were analyzed using
Origin 7.0 with an ITC add-on supplied by the manufacturer (Microcal, Northampton, MA).

Fluorescence Polarization
The dissociation constant (Kd,app) of the fluorescent probe, HGN-0201, for BpIspF was
evaluated using a Biotek Synergy 2 fluorescent plate reader. Purified IspF was spin concentrated
to 40 mg/ml using a 3,000 MWCO spin concentrator. The stock IspF was serially diluted in FP
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buffer (20mM sodium phosphate monobasic, pH 7.0, 300 mM NaCl, 2 mM DTT) to produce
final concentrations ranging from 0-500 μM with 100 μM HGN-0201 at 5% DMSO in a 96-well
black plate (Corning No. 3915). The plate was incubated at 30oC for 30 min followed by a 30 s
shake then read (λex = 330, λem = 528). The Kd,app was determined by nonlinear regression
analysis (Equation 3-1) in Origin 7.0 using the following relationship.118

;

Eq. 3-1

where Aobs is the observed anisotropy, Af and Ab are the anisotropy of the free and bound probe,
respectively, LT is the total probe (HGN-0201) concentration, RT is the concentration of enzyme,
and KD is the apparent dissociation constant of the probe. A schematic representation of the
instrumental setup is shown in Figure 3-2.
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Figure 3-2. Instrumental setup of fluorescence polarization assay using a Fluoromax 4
Spectrofluorimeter. Fluorophore is excited with a short pulse of vertically polarized light (z) that
causes photoselection. The polarizer (x) can be rotated from the vertical to horizontal position.
The decay of vertically polarized fluorescence (Ivv) is measured then the polarizer is moved to
the horizontal orientation (Ivh) to be detected.135
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Results and Discussion
Determination of Dissociation Constants by Surface Plasmon Resonance (SPR)
Due to the labor-intensive nature of the enzyme inhibition assays, it was determined that
Surface Plasmon Resonance (SPR) would be utilized as the primary method for measuring the
dissociation constant of inhibitors targeting BpIspF. The dissociation constants, Kd,app, were
determined using steady-state equilibrium experiments. The first ligands that were screened, the
fusion series,136 were designed to link the zinc and cytidine active site sub-pockets thereby
providing mimetics of the IspF substrate (Table 3-1). These were hypothesized to enhance
affinity compared to the control cytidine diphosphate (CDP) (Figure 1-16). Cytidine diphosphate
was found to bind with a stoichiometry of one with a Kd,app of 75 µM (Table 3-1). This was
examined via the synthesis of four, diverse zinc binding groups synthesized by Zheng Zhang:
imidazothiazole, thiazole, pyridine, and azabenzimidazole. To investigate these interactions with
the enzyme the compounds were analyzed by in silico docking using SYBYL X-2.0. Docking
studies provided predicted KD values (as pKD values). As shown in Table 3-1 these values were
comparable to experimental Kd,app values determined using SPR, which ranged from 70-200 µM.
The zinc binding moieties were predicted to direct the major conformational differences
observed in the docking poses (Figure 3-3). For example, compound HGN-0006 has a watermediated hydrogen bond to the active site zinc ion, while HGN-0007 has no interaction with the
zinc ion in comparison to HGN-0006. The interaction with the zinc ion in HGN-0006 was
hypothesized to increase the affinity of the ligand due to the additional point of interaction with
the enzyme.
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Table 3-1. Binding affinity and stoichiometry of fusion series by SPR utilizing cytidine
diphosphate as a control compound. Docking studies were done using SYBYL X-2.0 where pKD,
predicted log KD, were determined that correlate to SPR Kd,app values. *SPR ran by Sriram
Jakkaraju.
Compound

SPR Kd,app

SPR Estimated
Stoichiometry

Docking Score
(pKD)

(μM)

CDP

75

1:1

N.A.

HGN-0005

180

3:1

8.11

HGN-0009

148

3:1

8.34

HGN-0006

70

3:1

8.91

HGN-0008

200

3:1

7.13

HGN-0007

90

3:1

8.45
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Figure 3-3. Docking of HGN-0006 and HGN-0007 in the active site of BpIspF (cyan) displays
structural differences in modes of binding. HGN-0006 (magenta) coordinates to zinc (blue
sphere) via a water-bridge (red sphere) while HGN-0007 (yellow) has no interaction with zinc.
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To identify new fragment hits that bind to MEP pathway enzymes, Saturation Transfer
Difference (STD) NMR experiments were performed using Mycobacterium paratuberculosis
IspD, Mycobacterium abscessus IspE, and Burkholderia pseudomallei IspF by Dr. Darren
Begley (SSGCID). As shown in Figure 3-4, the NMR experiments were able to detect molecules
that bound to IspD, IspE, and IspF. Analogs of FOL955 (synthesized, by Zheng Zhang and
Gashaw Goshu) where N1 in the imidazole ring was moved to C5 for ease of synthesis and
derivatization at N5 (Figure 3-6). A series of twenty analogs were synthesized and screened
using SPR to determine dissociation constants and initial structure-activity relationships (SAR).
The compound L-tryptophan hydroxamate was used as a control ligand for the imidazole series.
It was reported to bind to Escherichia coli IspF with a Kd,app of 2 µM using SPR.106 The ligand
was found to bind to BpIspF with a Kd,app of 60  3 µM (Figure 3-5).
SPR analysis of the imidazole compounds was completed starting with the benzyl
derivatives including fluoro- substituted analogs, e.g. HGN-0095, which in general were better
than the chloro- substituted analogs, e.g. HGN-0051. The compound HGN-0021, a benzylsubstituted imidazole, was shown to be essentially inactive with a Kd,app >2,000 µM. Analogs
containing chlorine or fluorine were hypothesized to increase favorable interactions with the
enzyme in the cytidine pocket (Figure 1-16). Due to the higher polarizability of chlorine these
analogs could have an increased affinity for the enzyme in comparison to the fluoro-substituted
analogs.137 Relative to HGN-0021, the fluorine substituted benzyl analogs at the ortho- (HGN0106) and para- (HGN-0093) positions were determined to be effectively equal in potency with
dissociation constants of 96 µM and 83 µM, respectively. In comparison, a fluorine substituent
on the meta- position, HGN-0109, increased the affinity two-fold to 45 µM suggesting that at the
meta- position fluorine may introduce more favorable interactions with the enzyme via electron
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donating amino acids. The chlorine substituted benzyl analogs, HGN-0090 and HGN-0094, were
found to enhance binding affinity when substituted at the meta- (Kd,app = 22 µM) and para- (Kd,app
= 21 µM) positions but inactive in the ortho-position (HGN-0091). Since chlorine has a larger
electron density, they may be interacting more strongly with electron donating groups in the
active site of the enzyme but absent when in the ortho- position. Analysis of the disubstituted
chlorobenzyl analog HGN-0092 was found to be inactive, which could be due to deactivation of
the ring with the addition of the second chlorine molecule.
The phenethyl derivatives corresponding to the above compounds were also evaluated.
Compound HGN-0022 was found to be inactive (Kd,app > 2000 µM) suggesting that unsubstituted
analogs may not be able to interact with the enzyme to the same extent as those containing a
halogen. The fluorine analogs were determined to be more active than the chlorine substituted
analogs. The compound HGN-0097 contained a m-fluoro substituent and was found to be
inactive while HGN-0109, a m-fluoro benzyl analog, bound to the enzyme with a Kd,app of 45
µM. The decrease in affinity is most likely due to the loss of the fluorine interacting with the
electron donating amino acid, such as E137, because it was moved further into the cytidine
pocket when the linker was extended. The ortho- (HGN-0107) had an SPR Kd,app of 51 µM
showing an enhanced affinity as did the para- (HGN-0095) with a Kd,app of 36 µM. The increase
in the affinity from the benzyl analogs are opposite from the observation with HGN-0109. The
linker extension for the ortho- and para-fluoro (HGN-0095 and HGN-0107) phenethyl
substituted compounds appears to introduce additional favorable interactions with the enzyme
enhancing ligand affinity for the enzyme in comparison to the benzyl analogs (HGN-0093 and
HGN-0106). Overall, the mono- and disubstituted chlorine analogs were not active against
BpIspF with an SPR Kd,app >2,000 µM. The linker length in the monosubstituted chlorine
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compounds HGN-0096, HGN-0108, and HGN-0051 are bringing the substituent closer to the
cytosine pocket. Since the cytosine pocket does not contain electron-donating groups for the
chlorine it is binding similar to HGN-0022. Furthermore, the disubstituted analogs (HGN-0098,
HGN-0099, and HGN-0100) deactivate the ring which decreases its affinity for the enzyme.
Finally, a fluorescent ligand, HGN-0201, was developed for use in a potential
fluorescence polarization assay. The dansyl chloride group has previously been used in literature
to modify amines, carboxylic acids, and hydroxyl functional groups to fluorescently label small
molecules.138 The compound, HGN-0201, was determined to have an SPR Kd,app of 78 µM.
Although, the fluorescent compound was hypothesized to bind through the imidazole nitrogen, as
indicated by the crystal structure of FOL955 (Figure 3-6), there are alternative modes by which
the ligand may interact with the active site zinc ion. It is possible that HGN-0201 could also bind
through the sulfonamide or the phenol. The latter group also lends itself to the ready synthesis of
new IspF inhibitors.

Figure 3-4. STD-NMR screen identified seventy-two molecules that target BpIspF with three displayed (red). Additionally select
MpIspD fragment hits (cyan) and MaIspE fragment hits (black) identified in the screen are shown above.
110
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A

B

Figure 3-5. The determination of Kd,app of control, HGN-0003, screened from 7.81-1000 µM. (A)
SPR sensogram displaying the response in µRIU for each concentration tested and (B) semilogarithmic plot of the data from (A) demonstrating that the Kd,app as determined by SPR was
found to be 60  3 µM.

Table 3-2 continued
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Table 3-2. Binding affinity of imidazole series for Burkholderia pseudomallei IspF determined
by SPR utilizing L-tryptophan hydroxamate as a control.
Compound

Structure

Kd,app (µM)

FOL955

>2000 µM

HGN-0021

>2000 µM

HGN-0106

96 ± 2 µM

HGN-0109

45 ± 1 µM

Continued on following page
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HGN-0093

83 ± 2 µM

HGN-0091

>2000 µM

HGN-0090

22 ± 6 µM

HGN-0094

21 ± 2 µM

HGN-0092

>2000 µM

Continued on following page
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HGN-0022

>2000 µM

HGN-0107

51 ± 1 µM

HGN-0097

>2000 µM

HGN-0095

36 ± 1 µM

HGN-0096

>2000 µM

HGN-0108

>2000 µM

Continued on following page
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HGN-0051

>2000 µM

HGN-0098

>2000 µM

HGN-0099

Non-specific

HGN-0100

>2000 µM

HGN-0201

78 ± 8 µM

Continued on following page
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Figure 3-6. Structure of Burkholderia pseudomallei IspF in complex with FOL955. FOL955
(magenta) binds to zinc (blue sphere) of BpIspF (cyan) through the imidazole N with a bond
distance of 2.1Å.The crystal structure indicates substitution at the 5-position of the imidazole
ring will point towards the cytidine pocket. (PDB: 3QHD)90
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Analogs of FOL535 were synthesized by Gashaw Goshu with substituents on the 2, 5,
and 6- position of the imidazothiazole ring and screened using SPR (Table 3-3). The parent
compound (HGN-0245) was determined to bind to the enzyme with an affinity of 407 µM.
FOL535 (i.e., HGN-0245) was co-crystallized with Burkholderia pseudomallei IspF and found to
bind to the zinc through N7 of the imidazo[2,1-b]thiazole ring.90 Furthermore, FOL535 (HGN0245) provided a better initial dissociation constant as a starting scaffold to FOL955 which was
shown to bind with an affinity >2000 µM (Table 3-2). The analogs based on FOL535 were
synthesized with an amide rather than an ester linkage. There were two reasons for this decision:
ease of synthesis and lability of the bond. The ester can be more readily hydrolyzed to the acid
whereas the amide is stable. Substituents at C2, which point toward the lipophilic pocket,
indicated that the addition of large groups decreased the affinity of the ligand. This can be
observed by comparing HGN-0289, which bound with a dissociation constant of 210 µM, and
HGN-0282, which bound with a dissociation constant of 1200 µM. Therefore, the amide bond
improved binding affinity with small, hydrophobic groups in comparison to the fragment hit
FOL535 (HGN-0245). On the other hand, bulky hydrophobic substituents are unfavorable
because the pocket may not accommodate the size of the hydrophobic group, as observed in the
thermal-shift assay. Although HGN-0321 contains a bulky substituent at the 5-position as well as
the 2-position, it was found to have a Kd,app of 25 µM, which did not follow the observed SAR
with HGN-0282 and HGN-0289. The ligand, HGN-0321, could potentially chelate to the zinc
through the carbonyl which increases the chance of the pyridine ring to hydrogen bond with the
backbone of the enzyme in the cytidine pocket and accommodate the benzoyl substituent.
Alternatively, the compound could coordinate to the zinc through the pyridyl nitrogen similar to
the observed binding of FOL8395 (PDB: 3JVH)90.
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In addition, analogs were made with the hit molecule FOL717 (HGN-0247) identified in
the STD-NMR screen that bound with the same affinity as HGN-0289 with a KD of 210 µM, due
to a hydrogen bond between the primary alcohol and K134 (Figure 3-7). The substituent on the
imidazole ring points towards the cytidine pocket, which can accommodate larger substituents
and have more interactions with the backbone of the enzyme, Ala102 to Ala108. Therefore,
HGN-0381 was designed to add a hydrogen bond donor groups that extends into the cytidine
pocket. However, the compound was determined to have a decreased affinity (Kd,app 620 µM).
This decrease in affinity could be due to N7 of the imidazole ring not being at a bonding distance
with the zinc ion and therefore increasing the linker length could restore affinity. Additionally,
the imidazothiazole core was substituted with a different zinc binding group, a pyridine ring, to
determine the effect of changing the core. Two compounds were synthesized, HGN-0316 and
HGN-0317, which altered the position of the nitrogen in the ring. SPR results revealed that the
nitrogen in the 4-position had a higher affinity for the enzyme with a Kd,app of 855 µM for HGN0316 whereas with the nitrogen in the 3-position as for HGN-0317 it was only 1360 µM. The
two compounds containing the pyridine ring displayed a decrease in binding affinity due to the
increased flexibility within the molecule. Overall, maintaining the rigidity of the ligands with the
imidazothiazole core while including hydrophobic interactions with the lipophilic pocket and
hydrogen bonding with the cytidine pocket seem to result in increased binding affinity.

Table 3-3 continued
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Table 3-3. Binding affinity of imidazothiazole compounds to BpIspF using SPR with Ltryptophan hydroxamate as control at 25°C.

Compound

Structure

Kd,app (µM)

HGN-0245

407 ± 8

HGN-0289

210 ± 60

HGN-0282

1200 ± 3

HGN-0321

25 ± 1

HGN-0247

210 ± 10

Continued on following page
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HGN-0318

620 ± 9

HGN-0316

855 ± 8

HGN-0317

1360 ± 3

Continued on following page
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Figure 3-7. Structure of the BpIspF (cyan) active site in complex with FOL535 and FOL717.
Substituents at the 2-position of FOL535 (yellow), are observed to bind in the lipophilic pocket
while substituents at the 6-position of FOL717 (magenta) bind in the ribose pocket of BpIspF.
(PDB: 3K14 and 3MBM)90

Continued on following page
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Thermodynamic Analysis of Binding by Isothermal Titration Calorimetry (ITC)
ITC was used as an alternative method to study dissociation constants as well as the
underlying thermodynamics of inhibitor binding to trimeric IspF. Two structurally similar fusion
compounds, HGN-0006 and HGN-0009, were investigated to analyze the thermodynamic
contributions of binding HGN-0006 (Figure 3-8), HGN-0009, and the control cytidine
diphosphate. ITC revealed a stoichiometry of three with the fusion compounds in comparison to
CDP, which bound one molecule to the homotrimer. Additionally, the control compound CDP
had a much larger enthalpic contribution to binding the target, BpIspF. The ITC binding affinity
was in close agreement to the Kd,app values of the two fusion compounds determined by SPR.
Using the assumption that ligand-protein interactions dominates the enthalpic contribution,
optimizing this parameter can be used to guide the synthesis of more potent compounds.139 Since
both HGN-0006 and HGN-0009 displayed a significantly less favorable enthalpic contributions
than CDP, which had a ∆H of -24.7 kcal/mol, modification of CDP would likely lead to
compounds that bind with a higher affinity. Although, CDP has a significant unfavorable
entropic contribution of binding to BpIspF, -T∆S of 19.4 kcal/mol, and balancing enthalpic and
entropic contributions of binding need to be considered to increase affinity (Table 3-4).
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Table 3-4. Thermodynamic analysis of imidazothiazole fusion compounds binding to BpIspF by
ITC.

N

∆G°
(kcal/mol)

∆H°
(kcal/mol)

0.84 ± 0.01

5.28 ± 0.05

-24.7 ± 0.5

45.87 ±
0.08

3±0
(fixed)

5.916 ± 0.002

22 ± 1

3±0
(fixed)

Compound

pH

Kd,app (μM)

CDP

7.4

134 ± 5

HGN-0009

7.4

HGN-0006

7.4

6.35 ± 0.05

-5.95 ± 0.07

-8.61 ± 0.02

-T∆S°
(kcal/mol)
19.4 ± 0.5
0.03 ± 0.07

2.25 ± 0.05

Figure 3-8. ITC titration of HGN-0006 with Burkholderia pseudomallei IspF to determine Kd,app
at physiological pH and 25°C.
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The SPR control compound L-tryptophan hydroxamate, HGN-0003, was also studied
using ITC, along with the D-enantiomer and their L- and D- amino acids. This allowed
determination of the thermodynamic contributions of the hydroxamate moiety and enantiomeric
specificity. The L- and D-hydroxamates were both shown to bind more tightly than L- and Dtryptophan and BpIspF was more specific for the L-enantiomer (Table 3-5). Overall, the
thermodynamic analysis at pH 7.4 indicates the binding of the L- and D-tryptophan hydroxamate
analogs to the enzyme were enthalpically-driven with small entropic contributions. Based on the
structure of IspF, the stoichiometry was expected to be either 1.0 or 3.0. The binding
stoichiometry of L-tryptophan hydroxamate was 1.4, which suggests just over one ligand binding
to the IspF trimer (Figure 3-9). Thelemann, et al, observed a similar binding stoichiometry of 1.4
in the bis-sulfonamides with Arabidopsis thaliana IspF. 115 In comparison, the D-tryptophan
hydroxamate was found to have approximately less than one ligand (N=0.7) binding to the IspF
trimer with a two-fold decrease in affinity. The observed differences in stoichiometry may likely
reflect issues in determining an accurate concentration of the ligand, with a true stoichiometry of
1:1. This may be due to the hydroxamate moiety changing the extinction coefficient of
tryptophan, which was used for concentration determination. Due to weak binding affinities, a
sigmoidal binding titration was not observed in initial ITC experiments of D- and L-tryptophan
using a 10:1 ratio. The experiment was then run at 100:1 ratio, due to the low c-value, and the
stoichiometry was correspondingly fixed during model fitting.140 Additionally, L-tryptophan
hydroxamate was studied at a slightly lower pH (6.0) to explore the affinity under crystallization
pH conditions. The binding of the ligand under the slightly acidic pH condition was ~20-fold
weaker and was entropically driven. The pH dependent binding event could be explained by a
change in protonation of the enzyme or ligand between the two pH values, 7.4 to 6.0.
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Table 3-5. Tryptophan and tryptophan hydroxamate binding affinities determined differences in
binding affinity for BpIspF by ITC at 25°C. pH dependent binding was observed in HGN-0003
which can be used to optimize crystallization conditions due to ligands binding more favorably
under physiological conditions.

Compound pH

Kd,app
N

∆G° (kcal/mol)

∆H° (kcal/mol)

-T∆S° (kcal/mol)

-6.649 ± 0.002

2.1 ± 0.1

1.1 ± 0.2

-5.2 ± 0.2

(μM)

HGN-0003/

7.4

30 ± 2

1.4

6.2 ± 0.1

Ltryptophan
hydroxamate
HGN-0003/

4.19 ± 0.01

6.0

848 ± 2

1

7.4

64 ± 7

0.7

5.7 ± 0.1

Ltryptophan

7.4

>1,000

1

-

-

-

Dtryptophan

7.4

>1,000

1

-

-

-

Ltryptophan
hydroxamate
HGN-0778/

-6.650 ± 0.001

0.9 ± 0.1

Dtryptophan
hydroxamate
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Figure 3-9. ITC titration of HGN-0003 with Burkholderia pseudomallei IspF to determine Kd,app
at physiological pH and 25°C.
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Development of a Fluorescence Polarization Assay (FP)
To explore an alternative approach to assess dissociation constants, Kd,app, in a highthroughput manner, a fluorescence polarization assay was developed. Specifically, the goal was
to develop a competitive fluorescence polarization assay in which a library of inhibitors could be
screened in a plate-based assay to identify compounds which competed for the same active site.
The fluorescent molecule HGN-0201 was synthesized with the imidazole moiety utilizing a
dansyl group as the fluorophore. The methodology behind fluorescence polarization is that the
fluorophore’s degree of polarization is inversely proportional to its molecular rotation. Once the
fluorophore is bound to the macromolecule of interest, in this case Burkholderia pseudomallei
IspF, it will slow down the molecule’s rotation increasing its fluorescence polarization signal
(Figure 3-10). The fluorescent properties of HGN-0201 were analyzed, including the excitation
and emission spectra. The absorbance of the molecule was measured from 300-550 nm with a
λmax of 330 nm (Figure 3-11a). Analogously, the emission profile was collected from 350-750
nm, which possessed a λmax of 548 nm (Figure 3-11b).
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Fluorophore

Fast Rotation
Low Polarization

Slow Rotation
High Polarization

Figure 3-10. Illustration of fluorescence polarization principle of enzyme binding fluorophore
Fluorescence polarization of the small molecule will be low initially due to it rotating quickly in
solution. When macromolecule is added into the solution and as the ligand binds it will decrease
the rate at which the ligand rotates and give a high polarization. The polarization value increases
as more ligand binds to the macromolecule.
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Figure 3-11. Wavelength scans of HGN-0201 for determination of λmax values. (A) Excitation
scan of HGN-0201 identified a λmax at 330 nm. (B) Emission scan of HGN-0201 identified a λmax
at 548 nm.
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The dissociation constant of HGN-0201 for Burkholderia pseudomallei IspF was
determined using fluorescence polarization/anisotropy. The triplicate data set determined the
Kd,app to be 102.7 ± 9.8 µM (Figure 3-12). A competitive assay with 0-700 µM L-tryptophan
hydroxamate was then attempted with 150 µM BpIspF, the concentration at which approximately
50% binding was observed. Overall the experimental data were inconsistent in the competitive
assay and the Kd,app value of the ligand was not determined based upon this methodology. The
anisotropy value determined at 50% binding was lower than the value measure in the binding
assay of 5-(dimethylamino)-N-(2-(5-(4-hydroxyphenyl)-1H-imidazol-1-yl)ethyl)naphthalene-1sulfonamide, HGN-0201. Scans of the competitive ligand displayed overlapping of the
fluorescent signal, which interfered with the measured anisotropy values (data not shown).
Therefore, a competitive assay was not viable with the current fluorescent molecule.
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Figure 3-12. Fluorescence polarization titration of BpIspF with HGN-0201 determined the
dissociation constant to be 102.7 ± 9.8 µM.
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Conclusion
The binding affinity of several groups of potential IspF inhibitors including the fusion
series, imidazole series, imidazothiazole series, and tryptophan series were assessed using ITC
and SPR. The fusion compounds, which were designed to link the cytidine and zinc binding
pockets, were found to have the same affinity for the target in comparison to the control CDP. In
silico studies were performed for the fusion compounds, which were able to predict the rank
order of affinity that was observed by SPR. In addition, the mode of ligand binding was
predicted by docking where HGN-0006 coordinates to zinc through a water-mediated hydrogen
bond. Furthermore, the docking pose suggested the zinc-binding moiety of HGN-0009 does not
coordinate to the metal ion, which is in agreement with its weaker affinity for BpIspF. ITC
binding studies of two structurally similar fusion compounds, only differing by a methylene
group, determined the binding was enthalpically driven. The addition of a methylene group
decreased the enthalpic contribution by 2.66 kcal/mol likely due to moving the zinc binding
moiety away from the active site zinc.
L-tryptophan hydroxamate had been previously shown to bind to E. coli IspF and was
studied as an IspF control compound using both ITC and SPR. The compound was observed to
bind with an affinity of 30 ± 2 µM by ITC and 60  3 µM by SPR. The D-tryptophan
hydroxamate and the tryptophan enantiomers were also studied by ITC to determine the
enantiomeric selectivity, as well as the importance of the hydroxamate functional group. The
tryptophan enantiomers were found to bind with weak affinity >1000 µM indicating the
hydroxamic acid group is important for increasing the binding affinity for BpIspF. Additionally,
the L- tryptophan hydroxamate was found to bind more tightly to the enzyme with a KD of 30
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µM relative to the D-tryptophan hydroxamate with a KD of 64 µM. The binding affinities of the
tryptophan compounds were found to correlate to the thermal-shift analysis (Table 2-5).
To identify novel molecules that target the BpIspF active site, STD-NMR experiments
were used, revealing BpIspF bound several compounds from the Fragments of Life (FOL) library
including FOL955, FOL535, and FOL717. A series of analogs based on FOL955 were studied
for binding by SPR that were established to have Kd,app ranging from 20 µM to greater than 2000
µM. Compounds containing a fluorine substituent in the ortho and para position were observed
to bind more tightly than the chlorine substituted analogs in the phenethyl series. The meta and
para chloro benzyl substituents were shown to bind more tightly than the flouro substituents in
the imidazole series. In particular, a fluorescently labeled imidazole compound, HGN-0201,
which possessed a dansyl group had a Kd,app of 78 µM, opening its possible use in fluorescence
polarization assays. Analogs of FOL535 and FOL717 were studied by SPR and were found to
have Kd,app ranging from 210-1360 µM. Analogs of HGN-0321, which potentially interacts with
IspF’s active site zinc ion through the 5-postion carbonyl, where the electron acceptor oxygen is
not present, would give insight into the mode of binding. Alternatively, HGN-0321 could bind
through the pyridyl nitrogen observed with FOL8395 (PDB: 3JVH)90 which can be examined
using an analog which does not contain the carbonyl at the 5-position. Furthermore, analogs of
HGN-0321 could lead to more potent inhibitors of BpIspF. The thermal-shift assay (Chapter 2)
was able to provide insight about relative affinities of the compounds, but unfortunately,
correlation to the experimentally determined dissociation constants did not agree. This was
particularly evident in the imidazole series. The FP assay was able to successfully measure the
affinity at 102 µM, but the development of a competitive assay was not effective due to
interference of the fluorophore signal by the competitive ligands.

CHAPTER 4
DEVELOPMENT OF AN ISPF ENZYME INHIBITION ASSAY USING HIGHPERFORMANCE LIQUID CHROMATOGRAPHY

Although ligands studied in Chapter 3 bind the IspF enzyme, whether the compounds
inhibit IspF activity is not known. Therefore, the development of an assay to study the effect of
the compounds on enzyme activity, as well as SAR was essential. Bitok, et. al, previously
reported a high performance liquid chromatography (HPLC) assay to analyze enzymatic activity
of IspF (Figure 4-1).81 This assay monitors the cytosine chromophore that is present in both the
substrate, 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) and byproduct, cytidine monophosphate (CMP). Due to their identical chromophores, it is necessary to
separate the analytes of interest using an ion-pairing reagent. This chapter describes the synthesis
of the IspF substrate, CDP-ME2P, using the starting substrate MEP and two MEP pathway
enzymes IspD and IspE (Figure 4-2). IspF activity was analyzed in the absence and presence of
compounds to determine percent inhibition. Compounds were evaluated at a single concentration
(two-fold higher than the compound’s SPR-derived Kd,app). The data presented below
demonstrates that not all ligands that bind IspF inhibit the enzyme. Four of eleven compounds
analyzed in the HPLC assay were determined to inhibit IspF by >50%.
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Figure 4-1. IspF enzymatic reaction to convert CDP-ME to CDP-ME2P. The chromophore of the
substrate, CDP-ME2P (1), and the by-product, CMP (3), are monitored to determine the rate of
the IspF reaction at 272 nm.

Methods

General methods for preparation of 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate
(CDP-ME2P) and reaction rate determination of Burkholderia pseudomallei IspF were followed
as stated in Chapter 2.

HPLC-based IspF Activity with Inhibitors

The reaction rate determination of Burkholderia pseudomallei IspF were followed as stated in
Chapter 2 in the presence of IspF inhibitors. The final reaction mixtures contained 5% dimethyl

sulfoxide, which was used to facilitate small molecule solubility. Inhibitors were tested at a
concentration that was twice the measured Kd,app value to ensure the compound was in excess of
the protein. Percent inhibition was calculated using the Equation 4-1, where Ro is the rate of
reaction in the absence of inhibitor and Ri is the rate in the presence of inhibitor.81 Samples ran in
Caren Freel Meyers lab at John’s Hopkins School of Medicine.
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% Inhibition =

x 100

Eq. 4-1

Results and Discussion

Formation of 4-diphosphocytidyL-2C-methyl-D-erythritol 2-phosphate (CDP-ME2P)
The enzymatic synthesis of the IspF CDP-ME2P substrate was performed to allow
analysis of IspF enzymatic activity and its inhibition by inhibitors. The substrate, CDP-ME2P,
was formed via two enzymatic reactions from the starting material, 2C-methyl-D-erythritol 4phosphate (MEP), which was organically synthesized in a 7-step reaction sequence by the FreelMeyers Lab (Figure 4-2).141 The reaction was monitored using HPLC following absorbance at
272 nm. Both cytosine and adenosine nucleobases are observed in the chromatogram (Figure 43). The IspD reaction was monitored for the conversion of cytidine triphosphate, CTP (Sigma),
which transfers the cytidine monophosphate group to MEP, to form 4-diphosphocytidyl-2Cmethylerythritol, CDP-ME. The IspD reaction took 128 min for complete conversion to CDPME (Figure 4-4). The IspE reaction was performed in flux by addition of pyruvate kinase and its
substrate phosphoenol pyruvate (PEP) to regenerate ATP within the reaction. The reaction was
monitored for an additional 182 minutes during which time CDP-ME was converted to CDPME2P (Figure 4-5).
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Figure 4-2. The IspF substrate, CDP-ME2P, was generated using two enzymatic reactions in the
MEP pathway starting with synthesized 2C-methyl-D-erythritol 4-phosphate (MEP). The
reactions were completed in flux to ensure the IspD product was formed before addition of IspE.

Figure 4-3. Chromatogram of cytidine and adenosine nucleotides elution profile. Elution was
performed on an Altima C18 3µ, 53 mm x 7 mm Rocket column at 1.5 mL/min monitored at 272
nm. A linear gradient from 0-33.5% buffer B was used to elute the analytes of interest.
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Figure 4-4. The IspD reaction was monitored from 51 to 128 minutes. Conversion of CTP (tr =
3.10 min) to CDP-ME (tr = 2.15 min) was monitored. Slight degradation of CDP-ME to CDP (tr
= 2.00 min) can be observed in the chromatogram.
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Figure 4-5. Formation of CDP-ME2P monitored over time by following IspD and IspE reaction
progress at 272 nm. Listed times describe time post enzyme addition first for IspD (IspD), then
for IspE (IspDE). Conversion of CDP-ME (tr = 2.10 min) to CDP-ME2P (tr = 3.10 min) can be
observed in the chromatogram with ADP (tr = 3.80 min) and ATP (tr = 4.20 min).
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Determination of Burkholderia pseudomallei IspF Enzymatic Activity
After synthesis of the IspF substrate (CDP-ME2P) was completed and confirmed, the rate
of enzymatic activity for the Burkholderia pseudomallei IspF could be determined. The reaction
was initiated using 500 nM, 50 nM, and 2 nM IspF, which revealed 2 nM enzyme with 100 M
of substrate, where optimum conditions. The enzymatic reaction was found to be >90% complete
after 0.5 min using 50 nM and 500 nM IspF to initiate the reaction. Under these conditions the
rate of the enzymatic reaction could be measured from 0 to 45 minutes. Aliquots of the reaction
were quenched at 0, 0.5, 1, 2, 4, 6, 10, and 45 minutes to determine the concentration of CMP at
each time point (Figure 4-6, Figure 4-7). The reaction was 81% complete after 45 minutes with
an observed rate of 4.3  0.3 mol/min between 2 and 10 minutes (Figure 4-8). The rate of the
enzyme in absence of inhibitor was then used to calculate the percent inhibition.
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Figure 4-6. Enzymatic activity of BpIspF at 2 nM concentration. The reaction was monitored
from 0 to 45 minutes and determined to be >95% complete.
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Figure 4-7. Time course of CMP formation by BpIspF. The progress of the conversion of CDPME2P (tr = 3.0 min) to CMP (tr = 1.1 min) by BpIspF is demonstrated in this overlay of
chromatograms from 2 to 45 minutes. Reaction progress was monitored at 272 nm.
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Figure 4-8. Analysis of BpIspF rate through linear fit. A rate of 4.3  0.3 M/min was calculated.
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Inhibition of Burkholderia pseudomallei IspF
Single point screens of inhibitors were carried out to discover those that bound with Kd,app
value ≤210 M (Chapter 3, Table 4-1). Compounds were screened at concentrations that were
two times the Kd,app value, unless solubility was a limiting factor. Reaction time points were
taken at 2, 4, and 6 minutes to determine the rate of the inhibited reaction, which was fit using a
linear regression. To assess the extent of the reaction a sample was also taken at 45 minutes.
There were a total of eleven compounds screened in the HPLC assay to determine percent
inhibition (Table 4-1).
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Table 4-1. List of compounds screened in the HPLC enzyme inhibition assay displaying those
with a Kd,app values of ≤210 μM.
Compound

Structure

HGN-0003

N

Solubility

SPR Kd,app

>200 μM

60 μM

Enzyme Inhibition
Screen
120 μM

1000 μM

210 μM

400 μM

50 μM

210 μM

50 μM

100 μM

25 μM

50 μM

200 μM

22 μM

50 μM

200 μM

83 μM

200 μM

200 μM

21 μM

50 μM

200 μM

96 μM

200 μM

200 μM

45 μM

100 μM

200 μM

51 μM

100 μM

200 μM

78 μM

160 μM

NH2
N
O

OH

HGN-0247

N
N

HO

S

CH3

HGN-0289

O

N

CH3

N

S

N
CH3

HGN-0321

H3C

O
CH3
O

N
N

S

N
N

OH

HGN-0090

N

Cl

N

OH

HGN-0093

N
N
F
OH

HGN-0094

N
N
Cl

OH

HGN-0106

F
N
N

OH

HGN-0109

N
F

N

OH

HGN-0107

F
N
N
OH

HGN-0201

N
N

N

S O
O
N
H3C

CH3
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A total of four of the eleven compounds that were screened had greater than 50%
inhibition of Burkholderia pseudomallei IspF. The compound HGN-0003 (L-tryptophan
hydroxamate) which was previously identified to bind E. coli IspF106 and used as a control for
the binding assays, was run at a concentration of 120  to determine percent inhibition (Figure
4-9). The compound exhibited 55% inhibition with a rate of 1.74  0.4 mol/min (Figure 4-10).
The observed inhibition of BpIspF by L-tryptophan hydroxamate supports the notion that
compounds may bind across numerous IspF containing species.115,60,142 The three remaining
compounds that showed >50% enzyme inhibition were designed to bind to the active site zinc,
with two analogs based on the imidazole series and one on the imidazothiazoles. The compound
HGN-0107 was run at 100 for its single point inhibition screen (Figure 4-11). The compound
displayed 68% inhibition with a rate of 1.2 mol/min (Figure 4-12). A related analog HGN-0106
displayed 49% inhibition, suggesting the additional methylene group in compound HGN-0107
allows the ligand to interact more strongly with the electron donating group in the active site of
BpIspF to a greater extent than HGN-0106. In the imidazole analogs, placing the fluorosubstituent to the meta-position (HGN-0109) decreased the inhibitory effect while having it at
the para-position (HGN-0093) enhanced the activity of the enzyme. By comparison, having a
chloro- substituent on either the meta- or para- position (HGN-0090 and HGN-0094) did not
show significant inhibition of BpIspF. The fluorescent compound HGN-0201 was analyzed for
inhibition at 160 (Figure 4-13) and was determined to be the best inhibitor of IspF
discovered in this study, displaying 75% inhibition with a rate of 0.97 mol/min (Figure 4-14).
Although the rationale for synthesis of the imidazole series was based upon a hypothesis of
binding through the imidazole nitrogen, the fluorescent compound HGN-0201 also has the
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potential to bind through the sulfonamide. The results need further examination to determine the
exact mode of binding.
A total of three compounds in the imidazothiazole series: HGN-0245, HGN-0289, and
HGN-0321 were analyzed in the HPLC assay with HGN-0289 displaying an inhibitory effect
>50% on BpIspF. HGN-0289 was tested at 50 due to its lower solubility of the compound
(Figure 4-15). The compound displayed 57% inhibition with a rate of 1.6 mol/min (Figure 416). The original hit molecule from the STD-NMR screen HGN-0247 also displayed a weak
inhibitory effect at 400  with 32% inhibition, indicating a slightly bulkier functional group on
the thiazole ring increases activity. Finally, the rate observed for HGN-0321 was the same as the
enzyme in the presence 5% DMSO, thereby demonstrating that it is not a BpIspF inhibitor. The
substituents on the imidazothiazole ring are much bulkier than in HGN-0289 and these could be
causing steric clashes with active site side chains thereby preventing binding and leading to its
observed inactivity in the assays.

Figure 4-9. Determination of BpIspF inhibition by L-tryptophan hydroxamate. Aliquots of reaction were measure from 2 to 45 minutes
(bottom to top). Conversion of CDP-ME2P (tr = 3.0 min) to CMP (tr = 1.1 min) was monitored at 272 nm.
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Figure 4-10. Comparison of BpIspF rate in absence and presence of HGN-0003 (L-tryptophan
hydroxamate). The rate was determined to be 1.74  0.4 µmol/min at 120 

Figure 4-11. Determination of BpIspF inhibition by 4-(1-(2-fluorophenethyl)-1H-imidazol-5-yl)phenol (HGN-0107). Aliquots of
reaction were measure from 2 to 45 minutes (bottom to top). Conversion of CDP-ME2P (tr = 3.0 min) to CMP (tr = 1.1 min) was
monitored at 272 nm.
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Figure 4-12. Comparison of BpIspF rate in absence and presence of HGN-0107, 4-(1-(2fluorophenethyl)-1H-imidazol-5-yl)phenol. The rate was determined to be 1.22 µmol/min at 100
M.

Figure 4-13. HGN-0201 Determination of BpIspF inhibition by 5-(dimethylamino)-N-(2-(5-(4-hydroxyphenyl)-1H-imidazol-1yl)ethyl)naphthalene-1-sulfonamide, HGN-0201. Aliquots of reaction were measure from 2 to 45 minutes (bottom to top). Conversion
of CDP-ME2P (tr = 3.0 min) to CMP (tr = 1.1 min) was monitored at 272 nm.

152

153

Figure 4-14. Comparison of BpIspF rate in absence and presence of HGN-0201, 5(dimethylamino)-N-(2-(5-(4-hydroxyphenyl)-1H-imidazol-1-yl)ethyl)naphthalene-1sulfonamide. The rate was determined to be 0.97 µmol/min at 160 

Figure 4-15. Determination of BpIspF inhibition by N-isopropyl-3-methylimidazo[2,1-b]thiazole-2-carboxamide, HGN-0289.
Aliquots of reaction were measure from 2 to 45 minutes (bottom to top). Conversion of CDP-ME2P (tr = 3.0 min) to CMP (tr = 1.1
min) was monitored at 272 nm.
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Figure 4-16. Comparison of BpIspF rate in absence and presence of HGN-0289, N-isopropyl-3methylimidazo[2,1-b]thiazole-2-carboxamide. The rate was determined to be 1.64 µmol/min at
50 M.
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Bitok, et al. has previously shown that the substrate, MEP, is able to enhance E. coli IspF
activity.70 Therefore, BpIspF was also screened in the presence of 500  2C-methyl-Derythritol 4-phosphate (MEP) to examine potential enhancement of activity due to the presence
of the IspD substrate. The rate of conversion of CDP-ME2P to CMP by BpIspF was found to be
reduced to 3.3 mol/min in the presence of MEP (13% reduction). This value is within
experimental error of native BpIspF activity. Therefore, in this study, enhanced activity was not
observed in the presence of MEP.
The enzyme activity of BpIspF was also examined in the presence of DMSO, alone.
Since all reaction mixtures contained 5% DMSO to facilitate small molecule dissolution, it was
important to demonstrate that this component of the reaction buffers was not influencing activity
measurements. The activity of BpIspF in the presence of 5% DMSO was found to be 3.8
mol/min. This value is within experimental error of native activity and, therefore, DMSO was
demonstrated to have had no effect upon the experimental results.
Overall, out of the eleven compounds screened in the HPLC assay, four compounds
displayed >50% inhibition of Burkholderia pseudomallei IspF at concentrations two-fold above
the Kd,app value (Table 4-2). The result lends promise as these protocols and methods are further
refined.

Table 4-2 continued
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Table 4-2. Summary of BpIspF enzymatic rates in the presence of compounds.
Structure
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DMSO

Rate (µmol/min)

% Inhibition

3.82  0.3

-

1.74  0.4

54.5  0.2

2.68

29.8

1.64

57.1

3.71

-

2.59

32.2

3.15

-

N

NH2

HGN-0003

N
O

OH

N

HGN-0247
N

HO

S

CH3
O

N

HGN-0289

CH3

N

S

N
CH3

H3C

O
CH3
O

N

HGN-0321
N

S

N
N

OH

HGN-0090
N

Cl

N

OH

HGN-0094
N
N
Cl

Continued on following page

Table 4-2 continued

158
OH

HGN-0106

F

1.94

49.2

2.91

-

5.38

-

1.22

68.1

0.97

74.6

N
N

OH

HGN-0109
N
F

N

OH

HGN-0093
N
N
F

OH

HGN-0107

F
N
N

OH

HGN-0201
N
N

N
S

O

O
N

CH3

H3C

Continued on following page

159

Conclusions
An HPLC-based enzyme inhibition assay was successfully designed and implemented for
determination of single point, percent inhibition values. Using this assay, eleven potential
inhibitors were tested and four were found to generate ≥50% inhibition. The data also provided
insight into an initial SAR of the imidazole and imidazothiazole series. In the imidazole series,
ortho fluoro- substituent was found to be more potent than the chloro- substituent series.
Furthermore, extending the substituent with a two-carbon linker unit (HGN-0107) was found to
be more potent than a one carbon linker (HGN-0106). The inhibition studies were shown to
correlate to the FTS assay where the ortho fluoro- substituent displayed at shift of 3.2°C, for both
the benzyl and phenethyl analogs, and the ortho chloro- substituent had a shift of 2.5°C, benzyl
analog and 1.0°C, phenethyl analog. The fluorescent compound, HGN-0201, was determined to
have the best inhibitory effect observed for BpIspF with 75% inhibition, suggesting that the
bulkier functional group may have increased interactions with the enzyme. The molecule could
also be offering an alternative mode of binding through the sulfonamide rather than the
imidazole nitrogen and this moiety may even increase binding affinity to the active site zinc.
HPLC assay data for the imidazothiazole series are in agreement with SAR and SPR data
(Chapter 3), confirming that bulky functional groups on the thiazole ring (e.g., HGN-0321) are
likely not accommodated in the binding pocket. The enzyme inhibition data were based upon
single point runs, the lack of inhibition by HGN-0321, which had a KD of 25 µM, could be
within the error of the HPLC assay. Substitution of the ester linkage found in the original
fragment hit (HGN-0247 – 2.68 µmol/min) to and amide (HGN-0289 – 1.64 µmol/min)
generated greater than a two-fold increase in inhibition activity (57% inhibition at 50 µM) The
inhibition data showed good correlation to SPR KD values when comparing compounds that

160

were tested at the same concentration, with the exception of HGN-0093 which displayed enhance
IspF activity. The enhanced IspF activity with HGN-0093 would need to be studied further to
determine the error associated with the assay to conclude if there is actual enchantment of
activity. Based upon the findings of this study, the imidazole series appear to be the best
inhibitors of BpIspF tested to date.

CHAPTER 5
STRUCTURAL ANALYSIS OF INHIBITORS USING CRYSTALLOGRAPHY

The crystal structure of Burkholderia pseudomallei IspF is well documented in the protein data
bank (PDB), with over ten published structures.102 These IspF structures are either in complex
with low molecular weight ligands or are ligand-free. High resolution X-ray crystal structures of
inhibitor-enzyme complexes reveal atomic-level insight into the binding interactions. These
structures help illuminate existing interactions that drive the binding event, as well as provide a
path for potential design efforts to enhance ligand binding. Inhibitors that undergo structureguided modifications can be tested for increased or decreased potency in any number of assays
or biophysical techniques including additional crystal structures. It is this iterative process of
structure determination, insight, synthesis, assay, structure determination that constitutes the
basis of so-called rational drug design. To gain structural insight in the design of novel, highpotency BpIspF inhibitors, a structural biology component was explored. As a result, two high
resolution inhibitor-enzyme complex structures were determined for BpIspF bound to HGN-003
and HGN-0289 (Figure 5-1).
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Figure 5-1. Structures of L-tryptophan hydroxamate, HGN-0003, and N-isopropyl-3methylimidazo[2,1-b]thiazole-2-carboxamide, HGN-0289.

Methods

General methods for Crystallization of Burkholderia pseudomallei IspF, X-ray Diffraction, and
X-Ray Structure Solution were followed as stated in Chapter 2.

Co-Crystallization of Burkholderia pseudomallei IspF Inhibitors

Attempts to co-crystallize BpIspF with various inhibitors were undertaken. Briefly,
inhibitors were dissolved at 100 mM in DMSO. A total of 2.0 µL of DMSO solubilized inhibitor
was incubated with 8.0 µL of BpIspF at 32 mg/mL at 4oC for 2 hours. Samples were then
centrifuged at 14,000 rpm for 20 min at 4oC to remove potential precipitation that occurred
during incubation. Crystallization trials were performed manually using standard hanging drop
vapor diffusion methods in 24-well trays. Crystallization drops were composed of 1.0 µL
protein-inhibitor solution (~20 mM inhibitor, 25.6 mg/ml BpIspF in SE buffer) mixed with 1.0
µL crystallization buffer (100 mM Tris, pH 7.2, 200 mM NaCl, 20% PEG 4000, 5 0 mM
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inhibitor, 25.6 mg/ml B formate, pH 5.9, 20% PEG 3350). Crystallization tray well reservoirs
contained 1000 µL of crystallization buffer.90

Inhibitor Soaks with Burkholderia pseudomallei IspF

Attempts were also made to soak inhibitors into pre-formed, apo crystals of BpIspF.
Inhibitors were dissolved in methanol at 25 mM for these crystal soaks. For any given
compound, a 1.0 µL drop of inhibitor was added to a coverslip and allowed to evaporate to
dryness. The compound was then resuspended in 2.0 µL of crystallization buffer (100 mM Tris,
pH 7.2, 200 mM NaCl, 20% PEG 4000, 5 µM ZnCl2 or 200 mM C2H2MgO4∙2H2O, pH 5.9, 20%
PEG 3350) and two to three apo crystals were transferred to the drop. The coverslip was inverted
over a well on a crystal tray and sealed using vacuum grease. Well reservoirs contained 1000 µL
of crystallization buffer. Crystal trays containing these soaking experiments were incubated for
at least three weeks to maximize the possibility that compound would bind BpIspF.90

Results and Discussion

Burkholderia pseudomallei IspF Complex with L-tryptophan hydroxamate

L-tryptophan hydroxamate has been shown to be one of the highest affinity inhibitor of
BpIspF. The observed dissociation constant of the ligand was 30 µM (ITC-Chapter 3) and it
showed an inhibition of enzyme activity of 55% at 120 µM (HPLC-Chapter 4). While this
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compound was previously reported to be an EcIspF inhibitor (Kd,app of 2 µM),

106

the mode of

target binding was unknown.
The crystal structure of BpIspF with HGN-0003, determined at 1.47 Å, revealed a nontraditional mode of binding. HGN-0003 interacts with the active site zinc ion through the
primary amine as well as the amide nitrogen (Figure 5-2). The traditional mode of hydroxamic
acid binding to zinc has been shown to be mediated through either the carbonyl or hydroxyl
group with tetrahedral coordination. There are also some structures in which the hydroxamic
acid moiety of a compound bind the metal through both the carbonyl and hydroxyl group via
trigonal bipyramidal geometry (Figure 5-3).143,144,145,146 The ligand HGN-0003 was refined to an
occupancy of 1.0 with a B-factor of 25 Å2 (Figure 5-4). The bonding distance of the primary
amine to the zinc ion is ~1.9 Å, similar to the zinc bonding distances with Asp10, His12, and
His44. The ~2.9 Å bonding distance of the amide nitrogen to the zinc is slightly long for ideal
trigonal bipyramidal coordination but it is within measurement error. Finally, a water-mediated
hydrogen bond was observed between the backbone amide nitrogen of His36 and the hydroxyl
group of HGN-0003.
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Figure 5-2. The Burkholderia pseudomallei IspF crystal structure with HGN-0003 displays an
unusual mode of binding for the hydroxamic acid functional group to zinc. The ligand, HGN0003 (magenta) binds the zinc (blue) by filling out a trigonal pyramidal geometry coordination
sphere. The three BpIspF monomers in the trimeric enzyme are colored cyan (with bound
ligand), green, and light cyan.
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Figure 5-3. Known modes of hydroxamic acids binding to metal ions. Hydroxamic acids are
observed to chelate to metals through a) carbonyl and hydroxyl group (PDB: 4R7M, cyan),146 as
well as b) the carbonyl (PDB:5TLN, green).143

Figure 5-4. Electron density from the active site of BpIspF in complex with HGN-003. Clear
binding of the compound (magenta) to the zinc (blue sphere) is evident in this view. Electron
density is contoured at 1.5σ
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To help reveal potential structural differences between BpIspF and EcIspF that may lead
to the observed differences in binding affinities, the crystal structure of native E. coli IspF
(1JY8) was overlaid with the current structure of the L-tryptophan hydroxamate-B. pseudomallei
IspF complex (Figure 5-5). Based on the comparison of the two structures, there are no obvious
differences between the crystal structures to explain the difference in observed binding to HGN0003 (RMSDC = 0.256 Å).
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Figure 5-5. Active site overlap of the structures of Burkholderia pseudomallei IspF in complex
with HGN-003 and Escherichia coli IspF. The EcIspF (green) crystal structure was aligned to
BpIspF (cyan) in complex with HGN-0003 (magenta) to illustrate potential structural differences
between the two enzymes as they relate to ligand binding residues.
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Burkholderia pseudomallei IspF Complex with HGN-0289

To guide the synthesis of ligands with increased affinity for BpIspF, the ligand, HGN0289, was co-crystallized with the enzyme (Figure 5-6a). HGN-0289 has an N-isopropyl-3methylimidazo[2,1-b]thiazole-2-carboxamide core with an isopropyl amide group attached to the
thiazole ring. The ligand was designed to bind to the zinc through the imidazole nitrogen. HGN0289 binds IspF with a dissociation constant of 210 µM (SPR- Chapter 3) and displays 57%
inhibition at 50 µM (HPLC assay-Chapter 4). Structural data, determined at 1.51

, confirmed

binding of the imidazole nitrogen to the zinc with the isopropyl amide functional group pointing
into the lipophilic pocket (Figure 5-6b). The crystal structure indicates that the addition of a
slightly bulkier functional group off the thiazole ring, in future synthetic efforts, could increase
interactions with the lipophilic pocket, something to be considered in future inhibitor design.
Furthermore, the addition of functional groups on C2 or C3 of the imidazole ring may lead to
higher affinity inhibitors due to increasing interactions in the lipophilic pocket. The ligand HGN0289 refined to an occupancy of 0.81 with a B-factor of 30 Å 2 (Figure 5-7). The ligand
coordinates with the zinc tetrahedrally through the imidazole nitrogen with a bond length of 1.9
Å. The ligand HGN-0289 was synthesized as an analog of a fragment identified from a NMR
STD screen, FOL535 (PDB: 3K14).
As shown in Figure 5-8, an overlay of the crystal structures of BpIspF with HGN-0289
and the fragment hit from the STD-NMR screen, FOL535, shows both ligands bind to the zinc
ion with a tetrahedral coordination (RMSD = 0.071 Å). For both structures, the lipophilic
substituent points into the lipophilic pocket, as would be expected. This suggests that extending
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into this pocket with a slightly bulkier lipophilic group may increase the affinity of the ligand by
providing more and better interactions with the enzyme via the sub-pocket.
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Figure 5-6. Ribbon representations of the co-crystal structure of BpIspF in complex with HGN0289. (A) Overview of the BpIspF trimer. HGN-0289 is shown bound to the cyan monomer. (B)
Close up of the active site providing details of HGN-0289 binding. HGN-0289 is pictured in
magenta and the zinc as a blue sphere. The tight binding interaction (1.9 ) between the
imidazole nitrogen of HGN-0289 and the zinc is evident in this view. Some BpIspF residues
involved in ligand binding are also shown (and labeled). Worthy of specific mention is the
orientation of the HGN-0289 propyl amide functional group with respect to the lipophilic pocket
(residues Phe63, Ile59, and Phe70 of the pocket are identified).
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Figure 5-7. Electron density for the active site of BpIspF in complex with HGN-0289. HGN-0289
(magenta) binds to zinc (gray) of BpIspF (yellow) via N7 of the imidazothiazole ring. The
electron density map displays both positive (green) and negative (red) in addition to density
which is occupied (blue) by BpIspF and HGN-0289.
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Figure 5-8. Overlay of active site atoms for BpIspF in complex with HGN-0289 and the ligand
from a published BpIspF co-crystal structure (PDB: 3K14). 90 The published ligand structure was
chosen for this comparison because it is the same molecule that was discovered as a BpIspF
fragment hit by STD-NMR screening (FOL535).
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Conclusion
The crystal structures of BpIspF in complex with HGN-0003 and HGN-0289 provide
insight to help drive future design strategies for both the tryptophan and N-isopropyl-3methylimidazo[2,1-b]thiazole-2-carboxamide scaffolds. The information could help lead to the
development of inhibitors with an increased affinity to the target Burkholderia pseudomallei
IspF. The structure of HGN-0003 indicates that extending functional groups off the indole ring
nitrogen or C2 into the ribose pocket may allow new interactions with the enzyme. In addition,
lipophilic substituents at C7 of the indole ring of tryptophan are hypothesized to extend into the
lipophilic pocket and increase the affinity of the ligand for BpIspF. Functional groups which
have electron donating and accepting groups that extend into the ribose and cytidine pocket are
hypothesized to lead to an increase in affinity for BpIspF, which was observed in HGN-0321
(Table 3-3). The development of methods to screen and produce BpIspF/inhibitor co-crystal
structures is a promising start for the use of X-ray crystallography in guiding the synthesis of
novel, high affinity compounds that can inhibit this important target.

Figure 5-8 Structure of HGN-0321, 3-methyl-5-(4-methylbenzoyl)-N-(pyridin-3ylmethyl)imidazo[2,1-b]thiazole-2-carboxamide, which showed a binding affinity of 25 M by
SPR (Table 3-3).

CHAPTER 6
OVERALL CONCLUSIONS

According to the World Health Organization in 2013, there were 1.5 million deaths due
to tuberculosis alone.147 In addition, the number of multi-drug resistant tuberculosis cases has
significantly increase from 31% in 1993 to 88% in 2014.148 Therefore, the demand for the
development of novel anti-infective agents has significantly increased in conjunction with the
decreasing number of FDA-approved anti-bacterials.6,7 As a result, there is a need to determine
new pathways to target bacteria and/or to develop novel classes of anti-infective agents. The goal
of this project was to identify potential small molecule inhibitors of Burkholderia pseudomallei
through targeting the fifth enzyme in the MEP pathway, IspF. Due to a 30% sequence identity of
IspF across eukaryotic and prokaryotic bacterial species,90 inhibitors of Burkholderia
pseudomallei could have the potential to target several infectious disease causing organisms.
The current methods to analyze inhibition of the IspF enzyme are based upon a labor-intensive
HPLC assay or a highly coupled plate-based assays.
To open new opportunities for the discovery of novel IspF inhibitors, the initial study
developed a new assay to assess the potency of potential small molecule inhibitors. Biophysical
characterization of Burkholderia pseudomallei IspF revealed the enzyme was extremely
thermostable with a melting temperature >100°C. Therefore, a protein engineering approach was
used to develop a thermal shift assay. Single-site IspF variants were generated with the aim of
destabilizing the interface of IspF’s three subunits. Several variants destabilized IspF
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significantly (by at least 30ºC), which allowed thermal melt analysis of small molecule
inhibitors to assess apparent binding affinity. Of equal importance, enzymatic activity of variant
Q151E was not affected by the mutation. The development of such an assay provided an
efficient, convenient method for rank ordering the apparent affinities. The thermal shift assay
was used to evaluate four chemical series of compounds in order to narrow down the number of
compounds for subsequent determination of the dissociation constants.
The binding affinities of several groups of potential IspF inhibitors including the fusion
series, imidazole series, imidazothiazole series, and tryptophan analogs were assessed using SPR
and ITC. The fusion compounds, which were designed to link the cytidine and zinc binding
pockets of the IspF active site, were found to have the same affinity for the target as the control,
CDP. The fusion compounds were further examined by in silico studies which were able to
predict the rank order of affinities that were observed by SPR. By further utilizing in silico
docking methods, the mode of ligand binding was predicted for both HGN-0006 and HGN-0009.
ITC binding studies were conducted on two structurally similar fusion compounds, HGN-0006
and HGN-0009. These compounds differ by only a single methylene group. The results show
that binding of both compounds was enthalpically-driven. The addition of a methylene group
decreased the enthalpic contribution by 2.66 kcal/mol. It is plausible that this decrease is coming
from a slight change in the orientation of the zinc binding moiety relative to the zinc along with
the entire compound shifting to accommodate the presence of the extra methylene group in the
active site.
Tryptophan analogs were also a focus of this study because of their historical precedent
as metal binders. L-tryptophan hydroxamate was previously shown to bind E. coli IspF. Here,
both L- and D-tryptophan hydroxamate enantiomers, as well as both tryptophan enantiomers,
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were studied by ITC and SPR. The L-tryptophan hydroxamate was observed to bind with
dissociation constants of 30 ± 2 M by ITC and 60  3 M by SPR. Whereas the D-enantiomer
was found to bind to BpIspF slightly weaker (64 7 M by ITC). The tryptophan enantiomers
were found to bind with weak affinities, Kd >1000 M, indicating the hydroxamic acid group is
important for binding to BpIspF. The thermal shift assay also showed good correlation to SPR
and ITC binding affinity values for all compounds in the tryptophan series (Table 2-5).
STD-NMR experiments were used to identify new fragment hits that bind BpIspF. These
new hits served as a starting point for more detailed binding characterization using the primary
techniques and protocols developed in this study. A series of analogs were studied for binding by
SPR based on FOL955 that were established to have Kd,app ranging from 20 M to greater than
2000 M. Compounds containing a fluorine substituent were observed to bind more tightly than
the chlorine-substituted analogs. In particular, a fluorescently labeled derivative, HGN-0201, had
a Kd,app of 78 M. In addition to being a potentially exciting lead for further development, the
compound could potentially be used in fluorescence polarization assays. Analogs of fragment
hits FOL535 and FOL717 were determined to have Kd,app values ranging from 25 to 1200 M.
One compound of particular interest that was developed from FOL535, HGN-0321, had one of
the better Kd,app values observed in this study: 25 M. The synthesis of more analogs of HGN0321 could lead to more exciting and potent inhibitors of BpIspF. The thermal-shift assay
(Chapter 2) was able to provide insight about relative affinities of the compounds, but it
unfortunately did not have a high degree of correlation to dissociation constants determined by
other, more reliable methods used in this study. In addition, an FP was used to accurately
measure the affinity of HGN-0201 for BpIspF: 102 M. However, the development of a
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competitive assay was not effective due to interference of the fluorophore signal by the ligands
that compete for active site binding in BpIspF. Finally, those compounds that were found to
have dissociation constants ≤200 M by SPR were also analyzed in the enzyme inhibition assay.
An enzyme inhibition assay was developed and used to screen eleven compounds for
single-point, percent inhibition determination. A total of four of the eleven compounds that were
tested using the assay displayed ≥50% inhibition. The fluorescent compound, HGN-0201, was
determined to have the best inhibitory effect on BpIspF with 75% inhibition. This suggests that
the bulkier functional group may increase interactions with the enzyme, thereby providing
another starting point for future inhibitor design. Additionally, the molecule has the potential to
have an alternative mode of binding through the sulfonamide, rather than via the expected
imidazole nitrogen mechanism, which could result in an increased affinity for the zinc.
Crystal structures for both HGN-0003 and HGN-0289 BpIspF complexes provided
potential insight into future design strategies of both the tryptophan and N-isopropyl-3methylimidazo[2,1-b]thiazole-2-carboxamide scaffolds. The information should help lead to the
development of inhibitors with increased affinities for the target Burkholderia pseudomallei
IspF. The structure of HGN-0003 indicates that extending functional groups off the indole ring
into the ribose pocket may create new interactions with the enzyme. In addition, electron
withdrawing or donating groups on the benzene ring of the tryptophan are hypothesized to affect
the affinity of the ligand. Functional groups that extend into the ribose and cytidine pocket could
lead to an increase in affinity for BpIspF, as this work has already shown with HGN-0321 (Table
3-3). This study’s structural insight into BpIspF inhibition will help guide the synthesis of novel
derivatives of these two chemical classes as well as others.
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This work started with compounds that had weak mM affinities and little potential for
further development and culminated with a scaffold having an encouraging 25 M affinity that
can be used to continue the development of novel anti-infective agents. A high-throughput assay
was developed to assess relative affinities of IspF inhibitors. This assay can be used to efficiently
identify those compounds to be moved forward for binding affinity analysis using SPR and ITC.
This study also delivered a method for reliable Kd,app determination so that only those
compounds with Kd,app values ≤200 µM could be identified for assessment with more laborintensive BpIspF inhibition evaluation. In closing, this work has succeeded in new method
development, as well as delivering sufficiently high-affinity, BpIspF-binding compounds. Both
aspects will aid the design of next-generation novel compounds that target BpIspF with drug-like
binding affinities, which may ultimately be used as new antibiotic treatments.
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APPENDIX A – EXPRESSION VECTOR OF Burkholderia pseudomallei IspF

Expression Vector AVA0421
Antibiotic marker: Ampicillin and Chloramphenicol
Sequencing primers: Novagen T7 promoter primer (5’→3’) and T7 terminator primer (3’→5’)
Notes:
 This is a T7 promoter-based expression vector constructed from pET14b (Novagen). The
cloned gene is expressed as an N-terminal fusion with a His6-3C cleavage site.
 Use BL21(DE3) or similar host cell for expression and standard expression and
purification condition or T7 and His-tag.
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Translation of DNAMAN1{RF+1}(1-550)
Universal code
Total amino acid number: 182, MW=19347
Max ORF starts at AA pos 1(may be DNA pos 1) for 182 AA (546 bases), MW=19347

1
1

His6-tag
10
20
30
40
50
60
ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGT
M A H H H H H H M G T L E A Q T Q G P G

61
21

70
80
90
100
110
120
TCGATGGATTTCAGAATCGGACAAGGCTACGACGTGCACCAGCTCGTTCCCGGACGCCCG
S M D F R I G Q G Y D V H Q L V P G R P

121
41

130
140
150
160
170
180
CTCATCATCGGCGGCGTGACGATCCCTTACGAGCGGGGGCTGCTCGGCCACTCGGACGCC
L I I G G V T I P Y E R G L L G H S D A

181
61

190
200
210
220
230
240
GACGTGCTGCTGCACGCGATCACCGACGCGCTCTTCGGCGCGGCGGCGCTCGGCGACATC
D V L L H A I T D A L F G A A A L G D I

241
81

250
260
270
280
290
300
GGCCGCCACTTCTCCGACACCGATCCGCGCTTCAAGGGCGCCGACAGCCGCGCGCTGTTG
G R H F S D T D P R F K G A D S R A L L

301
101

310
320
330
340
350
360
CGCGAATGCGCATCGCGCGTCGCGCAGGCGGGTTTTGCGATCCGCAACGTCGACAGCACG
R E C A S R V A Q A G F A I R N V D S T

361
121

370
380
390
400
410
420
ATCATCGCGCAGGCGCCGAAGCTCGCGCCGCATATCGACGCGATGCGCGCGAACATCGCG
I I A Q A P K L A P H I D A M R A N I A

421
141

430
440
450
460
470
480
GCCGATCTCGACTTGCCGCTCGATCGCGTGAACGTGAAGGCGAAGACGAACGAGAAGCTC
A D L D L P L D R V N V K A K T N E K L

481
161

490
500
510
520
530
540
GGCTATCTCGGGCGCGGTGAGGGGATCGAGGCGCAGGCGGCCGCGCTCGTCGTGCGCGAA
G Y L G R G E G I E A Q A A A L V V R E

541
181

550
560
570
GCGGCCGCGTGAAAACAGCACGAACAAGTTCTGCA
A A A

stop
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Full DNA sequence
TTCTCATGTTTGACAGCTTATCATCGATAAGCTTTAATGCGGTAGTTTATCACAGTTA
AATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAATGCGCTCATCGTCATC
CTCGGCACCGTCACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCG
GGCCTCTTGCGGGATATCGTCCATTCCGACAGCATCGCCAGTCACTATGGCGTGCTG
CTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCC
GACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTACTTGGAGCCACTATCGAC
TACGCGATCATGGCGACCACACCCGTCCTGTGGATATCCGGATATAGTTCCTCCTTT
CAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTATTG
CTCAGCGGTGGCAGCAGCCAACTCAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATC
CTCGAGCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGATGATG
GCTGCTGCCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGA
AACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTCGA
TCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTG
GCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTC
ATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTG
GGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAAC
CTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGAT
GCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTAT
CGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGC
AGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGG
CCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGT
CCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGA
CGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCAT
TATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTC
CAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTA
CCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGG
CGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCTATACCTTGTCTGCC
TCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGAATGGAAGCC
GGCGGCACCTCGCTAACGGATTCACCACTCCAAGAATTGGAGCCAATCAATTCTTGA
AGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATG
GTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGT
TTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAA
ATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCC
CTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGT
GAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGG
ATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGA
TGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGC
AAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCAC
CAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCT
GCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGG
ACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGA
TCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC
TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCA
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CTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTG
AGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTA
TCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAG
ATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTAC
TCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGA
AGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTG
AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCC
GGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGAT
ACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGT
AGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGG
CGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGC
AGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGA
AGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGC
ACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGC
CACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGG
AAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGA
GTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCG
AGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTT
CACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAG
CCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCCGACACCCG
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCG
AAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACA
GATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTC
TGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATG
CCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAG
AGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGT
GAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGG
GTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGC
ATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCA
GACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGAC
GTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAAC
CAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATG
CGCACCCGTGGCCAGGACCCAACGCTGCCCGAGATGCGCCGCGTGCGGCTGCTGGA
GATGGCGGACGCGATGGATATGTTCTGCCAAGGGTTGGTTTGCGCATTCACAGTTCT
CCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATCCGTTAGCGAGGTGCCG
CCGGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGCGGG
GAGGCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTTCCATGTGC
TCGCCGAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAGTGATCGAAGTTAGG
CTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCATCTACCTGC
CTGGACAGCATGGCCTGCAACGCGGGCATCCCGATGCCGCCGGAAGCGAGAAGAAT
CATAATGGGGAAGGCCATCCAGCCTCGCGTCGTGAACGCCAGCAAGACGTAGCCCA
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GCGCGTCGGCCGTAACAACACCATTTAAATGGAGTGGTTACAAATGGAGTGGTTAA
TTAACAACACCATTTGTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGC
CCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAG
GAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCATACCCACGCCGAA
ACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGG
CGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGT
CCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGG
AGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATA
CCATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTC
CTGGTTCGATGGATTTCAGAATCGGACAAGGCTACGACGTGCACCAGCTCGTTCCCG
GACGCCCGCTCATCATCGGCGGCGTGACGATCCCTTACGAGCGGGGGCTGCTCGGC
CACTCGGACGCCGACGTGCTGCTGCACGCGATCACCGACGCGCTCTTCGGCGCGGC
GGCGCTCGGCGACATCGGCCGCCACTTCTCCGACACCGATCCGCGCTTCAAGGGCGC
CGACAGCCGCGCGCTGTTGCGCGAATGCGCATCGCGCGTCGCGCAGGCGGGTTTTG
CGATCCGCAACGTCGACAGCACGATCATCGCGCAGGCGCCGAAGCTCGCGCCGCAT
ATCGACGCGATGCGCGCGAACATCGCGGCCGATCTCGACTTGCCGCTCGATCGCGTG
AACGTGAAGGCGAAGACGAACGAGAAGCTCGGCTATCTCGGGCGCGGTGAGGGGA
TCGAGGCGCAAGCGGCCGCGCTCGTCGTGCGCGAAGCGGCCGCGTGAAAACAGCAC
GAACAAGTTCTGCAGCCAAGCTTCTCGAGGATCCGGCTGCTAACAAAGCCCGAAAG
GAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGC
CTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCC
ACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
GCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGTGCTCCGAGAACGGGTG
CGCATAGAAATTGCATCAACGCATATAGCGCTAGCAGCACGCCATAGTGACTGGCG
ATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAA
GCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGT
TAGATTTCATACACGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGC
ATTAAAGCTTATCGATGATAAGCTGTCAAACATGAGAA

APPENDIX B – IMIDAZOLE SPR SENSOGRAMS
FOL955*
HGN-0021*
A

B

Figure B1. The dissociation constant of HGN-0106 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B2. The dissociation constant of HGN-0109 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined Kd,app
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A

B

Figure B3. The dissociation constant of HGN-0093 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B4. The dissociation constant of HGN-0091 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B5. The dissociation constant of HGN-0090 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B6. The dissociation constant of HGN-0094 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B7. The dissociation constant of HGN-0092 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B8. The dissociation constant of HGN-0022 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B9. The dissociation constant of HGN-0107 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B10. The dissociation constant of HGN-0097 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B11. The dissociation constant of HGN-0095 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B12. The dissociation constant of HGN-0096 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B13. The dissociation constant of HGN-0108 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B14. The dissociation constant of HGN-0051 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B15. The dissociation constant of HGN-0098 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.

A

B

Figure B16. The dissociation constant of HGN-0099 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure B17. The dissociation constant of HGN-0100 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure B18. The dissociation constant of HGN-0201 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
* Compounds were run by Sriram Jakkaraju and sensograms are not included.

APPENDIX C – IMIDAZOTHIAZOLE SPR SENSOGRAMS
A

B

Figure C1. The dissociation constant of HGN-0245 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A
B

Figure C2. The dissociation constant of HGN-0289 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure C3. The dissociation constant of HGN-0282 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.

A

B

Figure C4. The dissociation constant of HGN-0321 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
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A

B

Figure C5. The dissociation constant of HGN-0247 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.
A

B

Figure C6. The dissociation constant of HGN-0318 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.

211

A

B

Figure C7. The dissociation constant of HGN-0316 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.

A

B

Figure C8. The dissociation constant of HGN-0317 displaying A) Sensogram displaying the
response in µRIU for each concentration tested and B) semi-logarithmic plot to determined
Kd,app.

APPENDIX D – IDENTIFICATION OF NEW HIT COMPOUNDS FOR BpIspF
The use of a thermal-shift assay has been widely implemented to generate a rank ordering
of inhibitors for protein target binding.84,85,86,87,109 The shift in melting temperature in the
presence of inhibitors can be measured rapidly, >2000 compounds in an hour, which makes the
assay a powerful technique. Therefore, the development of an internal high throughput thermalshift assay for BpIspF was a critical alternative to STD-NMR, which had to be done in
collaboration with an exterior partner. The development of this assay for BpIspF was made more
challenging by the high thermal stability of the enzyme. However, a successful effort in rational,
point directed mutagenesis allowed the development of a form of BpIspF with sufficiently
decreased Tm, but retaining native activity, to allow for small molecules to be screened. Using
this assay, BpIspF could be screened against a library consisting of drug components from the
US, Europe, and Japan, natural products with known biological activity, and bioactive
compounds that include non-drug enzyme inhibitors, receptor blockers, membrane active
compounds, and cellular toxins. The library is called the Spectrum Collection (MicroSource
Discovery Systems, Inc.) and contains a total of 2400 compounds. The BpIspF Q151E variant
was screened against the entire library to identify new fragment hits.

Method:
General procedure for temperature-shift assay was followed as reported in Chapter 2.
Results:
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Screening for new lead compounds in the spectrum collection identified three chemical classes
of compounds that were found to change the melting temperature of BpIspF Q151E by >±4°C.
The first chemical class of compounds determined to have an apparent affinity for the
enzyme were -lactams, known to inhibit cell wall biosynthesis in bacteria.9,12 This class
constituted a total of eight compounds out of the fifty-six in the library (D1). Since only eight of
the fifty-six compounds in this class found in the library were identified by the assay, the
apparent affinities were not simply specific to the -lactam core.
The second class of compounds identified was sulfoxides, which are proton pump
inhibitors that reduce gastric acid production (D2). Sulfoxides have been found to be the most
potent inhibitors available for gastrointestinal acid secretion149 A total of only three out of thirtytwo sulfoxides found in the library were identified by the thermal-shift assay as hits against
BpIspF, once again showing that the assay was working selectively and that the enzyme is not
simply promiscuously binding sulfoxides.
The last class of compounds identified to have an apparent affinity for BpIspF was
sulfonamides, which inhibit folate synthesis (D3).150 Although sulfonamides were originally
identified as antibacterials, they have been found to also function as anticonvulsants, diuretics,
and anti-diabetic agents.151,152,153 Therefore, it is not surprising that this broad spectrum class
might also have potential activity against BpIspF. However, this might also prove problematic
for the ultimate development of a BpIspF drug from the class since there is clear precedent for
cross-reactivity to other systems. As for the other two classes identified by the assay, only three
of the eighty-four sulfonamides present in the library were identified as hits for BpIspF binding,
so this once again does not suggest simple promiscuity against an entire class.

Table D1 contintued
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Blind screening of chemical libraries to identify binders for a target molecule can lead to
false positives. The identification of false positive hits is particularly exacerbated when libraries
are populated with molecular classes that are known to be promiscuous binders, like the
catechols.154 Though, well designed libraries will minimize or totally eliminate such compound
classes since they serve little purpose for high specificity inhibitor design.154 To test the
applicability of the Spectrum Collection to the goals of this study, the library was also screened
against another enzyme in the MEP pathway, EcIspD. The fragment hits identified for BpIspF
were not the same compounds that showed apparent affinity for EcIspD, confirming that these
compounds were indeed BpIspF-specific, and not promiscuous, binders and that the library was
applicable to the goals of this study.

Table D1. List of -lactams identified in the thermal-shift assay at Northwestern University.
-lactams

Structure

ΔTm

Cefamandole

33.57

Cefonicid

28.48

Continued on following page

Table D1 contintued
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Cefoperazone

18.74

Cefazolin

17.95

Cefotaxime

10.93

Cefdinir

6.66

Cephradine

5.15

Azlocillin

4.55

Continued on following page
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Table D2. List of Sulfoxides identified in the thermal-shift assay at Northwestern University.
Sulfoxides

Structure

ΔTm

Lansoprazole

19.25

Esomeprazole

5.12

Rabeprazole

4.28

Table D3. List of Sulfonamides identified in the thermal-shift assay at Northwestern University.
Sulfonamides

Structure

ΔTm

Ethoxzolamide

10.31

Sulfapyridine

-5.62

Sulfamonoethoxine

-9.63

APPENDIX E – ANALYSIS OF INHIBITOR BINDING BY STD-NMR

The use of NMR to screen drug-like molecules was first reported in the 1990’s and has
been advancing rapidly over the years. NMR has become a powerful tool to study nucleic acid
and protein interactions with small molecules155 using Saturation-transfer difference NMR, or
STD-NMR. STD-NMR is a powerful technique that allows epitope mapping of small moleculeprotein interactions. This helps to determine which portion(s) of small molecule ligands are
within 5Å of the protein.122,156 The STD-NMR experiment depends on the exchange rate of
bound and unbound ligand (Figure E1) and nuclear Overhauser effect (NOE) to identify protons
which are interacting with the protein (Figure E2). Therefore, this approach can be utilized for
those compounds with a dissociation constant between 10-8 and 10-3 M due to the time scale
which NMR is capable of measuring (µs-s).157 Yet another limitation is that the concentration of
available ligand must be in great excess of the protein, typically by a factor of 50-100. Such high
concentrations can lead to problems with less soluble compounds and may result in non-specific
interactions.158 To avoid this limitation it is best to run compounds well below their solubility
limits.
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Figure E1. Scheme of a Saturation Transfer Difference – NMR Assay (STD-NMR). Adapted
from Viegas.157

Figure E2. Scheme of Nuclear Overhauser Effect to determine STD. Adapted from Begley.156
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Methods:
HGN-0201: NMR samples were prepared by diluting dialyzed protein (36 mg/mL) to 70
µM in D2O. Compound was assayed at a ligand concentration of 210 µM with 25 µL deuterated
dimethyl sulfoxide (d6-DMSO) in a 500 µL sample volume. All experiments were conducted on
a Varian Inova 500 MHz NMR spectrometer equipped with a 5 mm TBO BB-1H/13C/D Z-GRD
Z5723/0007 probe at a temperature of 25 °C. Screening was carried out using ligand-observed
proton-based one-dimensional STD-NMR. Briefly, 64 scans were acquired over a 16 ppm sweep
width at 32k scans, with a total recycle delay of 2.0 s. A low-power 15 ms spin-lock pulse was
added to filter out low-level protein peaks to suppress the bulk water signal. STD-NMR presaturation was completed using a 2.4 s long train of Gaussian-shaped pulses with a spectral width
of 500 Hz focused at -3 ppm, with reference irradiation set to 30 ppm. NMR spectra were
processed and analyzed using MestReNova (Mestrelab).

HGN-0003: NMR samples were prepared by diluting dialyzed protein (36 mg/mL) to 70
µM in D2O. Compound was assayed at ligand concentrations of 3500 µM with D2O present in a
500 µL sample volume. The general procedure was followed as reported for HGN-0201.

Results:
Two compounds were studied using one-dimensional STD-NMR to determine the
protons interacting with BpIspF. The compound, HGN-0201, synthesized for the development of
a fluorescence polarization assay, SPR derived KD of 78 µM, was studied at a ratio of 30:1 by
STD-NMR. Proton mapping was determined using difference NMR. Difference NMR indicated
the biphenyl ring, imidazole ring, phenol ring, and the N-dimethyl groups were in contact with
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the enzyme (Figure E3). Furthermore, knowledge of the protons that are not interacting with the
enzyme could be used to guide the synthesis of compounds that would potentially have increased
affinity for BpIspF.
In order to map specific interactions of the control compound, HGN-0003, to BpIspF, it
was also studied by STD-NMR. HGN-0003 was found to have a KD of 60 µM by SPR and a KD
of 30 µM by ITC. HGN-0003 was run at a 50:1 ratio in STD-NMR. A limitation of this
experiment was due to the exchangeable protons within HGN-0003, the amide NH proton and
amine protons. Since these protons rapidly exchange with deuterium they were not observed in
the NMR and could not be analyzed for interactions with the enzyme. The mapping of protons
observed in the NMR, which interact with the enzyme, was determined to be the indole ring as
well as the methylene group of HGN-0003 (Figure E4). Therefore, interactions of exchangeable
protons, found in the hydroxamate function group, indicated to be important for binding in the
crystal structure were not observed in the difference NMR.

Figure E3. Determination of HGN-0201 protons that are observe saturation transfer from BpIspF.
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Figure E4. Determination of HGN-0003 protons that observe saturation transfer from BpIspF.
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1

H NMR (300 MHz, CD3OD): δ 8.55 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 8.7 Hz, 1H), 8.02 (dd, J =

7.5 Hz, J = 1.2 Hz, 1H), 7.58 – 7.50 (m, 3H), 7.26 (d, J = 7.5 Hz, 1H), 7.05 – 7.02 (m, 2H), 6.83
– 6.80 (m, 2H), 6.76 (s, 1H), 4.03 (t, J = 6.6 Hz, 3H), 2.92 (t, J = 6.3 Hz, 3H), 2.88 (s, 6H).

(500 MHz, CD3OD): δ 7.62 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.13 – 7.09 (m, 2H),
7.05 – 7.02 (m, 1H), 3.53 (t, J = 7.0 Hz, 1H), 3.18 (dd, J = 14 Hz, J = 7.0 Hz, 1H), 3.00 (dd, J =
14 Hz,J = 7.0 Hz, 1H).

APPENDIX F – X-RAY CRYSTAL STRUCTURE STATISTICS
Table F1. Data processing and refinement statistics for BpIspF Q151E variant
Space Group

C121

abc

116.8, 68.1, 60.4

ɣ

90.0, 96.6, 90.0

Resolution

1.72

Completeness

1.0

# Unique Reflections

50230

Rwork/Rfree

0.1659/0.2036

Burkholderia pseudomallei IspF 463
Zn2+

3

H2O

458

RMSD
Bond length (Å)

0.011

Bond angle (o)

1.26

Ramachandran
Preferred (%)

0.98

Allowed (%)

0.02

Outliers (%)

0.0
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Table F2. Data processing and refinement statistics for BpIspF in complex with HGN-0003

Space Group

C121

abc

116.5, 68.1, 60.7

ɣ

90.0, 96.9, 90.0

Resolution

1.47

Completeness

0.99

# Reflections
Unique

79224

Rwork/Rfree

0.1800/0.1756

Res
Burkholderia pseudomallei IspF

474

Zn2+

3

H2O

435

RMSD
Bond length (Å)

0.011

Bond angle (o)

0.92

Ramachandran
Preferred (%)

0.99

Allowed (%)

0.01

Outliers (%)

0.0
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Table F3. Data processing and refinement statistics for BpIspF in complex with HGN-0289

Space Group

C121

abc

116.7, 67.9, 60.5

ɣ

90.0, 96.5, 90.0

Resolution

1.51

Completeness

1.00

# Reflections
Unique

73745

Rwork/Rfree

0.1548/0.1740

Res
Burkholderia pseudomallei IspF

458

Zn2+

3

H2O

459

RMSD
Bond length (Å)

0.014

Bond angle (o)

1.28

Ramachandran
Preferred (%)

0.99

Allowed (%)

0.01

Outliers (%)

0.0

